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THESIS ABSTRACT 
 
Background 
 
Liver ischaemia reperfusion injury (IRI) occurs after prolonged ischaemia followed by 
reperfusion in the clinical setting, such as liver resection surgery and liver transplantation and 
is associated with increased morbidity and mortality. Ischaemic preconditioning (IPC) is a 
therapeutic strategy to lessen liver IR injury. Liver IPC is a mechanical technique whereby a 
short period of occlusion of the blood supply to the liver confers protection against IR injury. 
Understanding the molecular mechanisms of IPC offers the possibility of developing 
techniques and pharmacological agents that will reduce IRI and improve clinical outcomes. 
 
Hypothesis, Aims and Objectives 
 
The molecular mechanisms of liver IPC are not clearly established. Nitric oxide is an 
important mediator, but the role of the activation and expression of nitric oxide synthase 
(NOS) and its isoforms endothelial NOS (eNOS) and inducible NOS (iNOS) is unclear. 
Haem oxygenase-1 (HO-1) protects, but it is unclear if this depends on NOS. There appear to 
be two phasese of liver IRI and IPC: an early and late phase. There is evidence that NOS has 
roles in both phases, but that HO-1 has a role only in the late phase. The principal aim was to 
develop a transgenic eNOS knockout (eNOS-/-) model of liver IRI and IPC to specifically 
probe the in vivo physiological roles of eNOS and its interactions with HO-1 these processes.  
 
Methods 
 
An in vivo mouse model of partial (70%) warm hepatic ischaemia reperfusion (IR) was used. 
Normal and transgenic double knockout for eNOS (eNOS-/-) mice were used. A partial warm 
liver IR model was used where ischaemia was applied to cephalic lobes only followed by 
reperfusion. Ischemic preconditioning (IPC) consisted of ischaemia applied directly to the 
cephalic lobes followed by reperfusion then IR to the cephalic lobes.  Final reperfusion was 
either for 2 hours (normal and eNOS-/- mice) representing early phase IRI or for 24 hours 
(normal mice) representing late phase IRI after which the animals were terminated for tissue 
and blood samples. The endpoints measured were surface laser Doppler flow to assess liver 
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microcirculation during the experiment and blood and liver tissue samples at the end of the 
experiment for serum ALT, liver histological injury scores, Western blotting for eNOS, 
iNOS, phosphorylated eNOS (p-eNOS), HO-1 protein and RT-PCR for HO-1 mRNA. 
 
Results  
 
1. In this model of early phase partial hepatic IR consisting of 45 minutes ischaemia to the 
cephalic lobes and 2 hours reperfusion (index IR), there was IRI in normal mice across the 
three endpoints for IRI of serum ALT, histological injury and microcirculatory dysfunction. 
IPC consisting of 5 minutes ischaemia and 10 minutes reperfusion (IPC 5/10) preceding index 
IR reduced IRI across the three endpoints in normal mice. In eNOS-/- knockout mice, there 
was also IRI across the three endpoints, with greater hepatocellular and histological injury 
than normal mice, but no difference in the microcirculatory dysfunction compared to normal 
mice. In eNOS-/- knockouts IPC 5/10 did not reduce IRI across the three endpoints. This 
indicates that eNOS is a mediator of the protective effects of IPC in early phase liver IRI and 
baseline eNOS reduces the severity of IRI even without IPC. Based on the differences on the 
effects on the endpoints between all the experimental groups, it appears that IPC protection is 
mediated by eNOS in hepatocytes and sinusoidal endothelial cells (SECs) and baseline eNOS 
protection in liver IR without IPC is mediated by hepatocyte eNOS only. 
 
2. It was demonstrated that in the early phase partial hepatic IR model that both IR and IPC 
increased eNOS protein expression and eNOS activation by phosphorylation with no 
additional effect of IPC. This indicates that the protective effect of eNOS with IR alone may 
at least be partly mediated by increased eNOS protein expression and activation by 
phosphorylation, but the benefits of IPC in reducing early phase IR injury are mediated by 
eNOS activation by other mechanisms. Expression of iNOS protein does not play a role in IR 
injury in our model.  Haem oxygenase-1 (HO-1) protein was not expressed in our model, but 
HO-1 mRNA was expressed in both normal and eNOS-/- animals following liver IR and IPC, 
indicating that HO-1 expression is not dependent on eNOS. HO-1 may therefore still have a 
protective effect in the late phase of IR injury acting in a parallel pathway to eNOS.  
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3. In the model of late phase partial (70%) hepatic IR consisting of 45 minutes ischaemia, 
recovery from anaesthetic and 24 hours reperfusion (index IR) developed using normal mice 
only, there was liver IRI across two endpoints of serum ALT and histological injury 
(microcirculatory dysfunction was not studied in the late phase) with progression of 
histological injury from mainly sinusoidal congestion to hepatocyte necrosis. IPC consisting 
of 5 minutes ischaemia and 10 minutes reperfusion (IPC 5/10) preceding index IR reduced 
IRI across the endpoints. HO-1 protein was detected with late phase IR and IPC, indicating  
timecourse of early phase HO-1 mRNA expression followed by late phase HO-1 protein 
expression. This is consistent with the possibility of HO-1 potentially having a protective role 
in late phase liver IR and IPC. 
 
 
 
Conclusions 
 
We have developed a model of early and late phase liver IRI and IPC, which has 
demonstrated that eNOS is a protective mediator in IRI and IPC in the early phase, HO-1 is 
activated independently of eNOS and may have a role in late phase IRI and IPC. This model 
should prove useful in investigating the roles of eNOS and HO-1 in liver IPC and IR injury. 
This would ultimately be used to identify pathways for development of pharmacological 
agents that would effectively reduce liver IR injury in the clinical setting and improve patient 
outcomes related to this. 
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CHAPTER 1 
 
BACKGROUND:  
 
1.1. Clinical Liver Ischaemia Reperfusion Injury and Therapeutic Interventions 
 
1.1.1. Introduction 
Ischaemia reperfusion injury (IRI) is a major cause of hepatic injury following temporary 
clamping of the hepatoduodenal ligament (Pringle manoeuvre) during liver resection surgery 
and liver transplantation. This injury is associated with posthepatectomy liver insufficiency 
and posttransplantation primary nonfunction (PNF) of a graft or initial poor function (IPF) 
(Huguet et al. 1992; Jaeschke et al. 1996; Rosen et al. 1998; Serracino-Inglott et al. 2001) 
Even moderate reperfusion injury that does not severely affect the graft can impair recovery 
of liver function and is a risk factor for patients developing postoperative sepsis and 
mulitorgan dysfunction or failure (Serracino-Inglott et al. 2001). Steatotic livers are 
particularly susceptible to IRI with its associated complications (Koneru et al.2002; Selzner 
et al. 2001). In this context and considering the shortage of suitable organ donors, therapeutic 
strategies have been explored looking at preconditioning livers to reduce the severity of IRI. 
 
1.1.2. Clinical relevance of Liver Ischaemia Reperfusion Injury 
During hepatic resection surgery bleeding from the cut liver surface can be a major problem. 
It has been well documented that occlusion of the portal vessels by clamping the 
hepatoduodenal ligament is a safe means of minimising intraoperative blood loss. Although 
this technique is effective in limiting blood loss, it increases the risk of liver ischaemia with 
resulting severe liver injury. With prolonged ischaemia, reperfusion can also cause injury 
which is a distinct entity from the ischaemic injury, called ischaemia reperfusion injury (IRI). 
Longer periods of continuous warm ischaemia are associated with worse liver IRI which 
translates into worse postoperative morbidity and mortality (Belghiti et al. 1999; Huguet et al. 
1992).  
The prolonged ischaemia results in depletion of ATP and accumulation of anaerobic 
metabolites. On reperfusion, sudden availability of oxygen to ischaemic tissues generates 
reactive oxygen species which directly injure cells and also activate injurious molecular 
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signalling pathways. This activates an inflammatory signalling cascade which leads to liver 
cell and tissue injury. The liver plays an important part in the metabolic stress response, 
detoxification, immunological function and synthesis of albumin and clotting factors. With 
severe injury, there is an impaired stress response associated with organ dysfunction, 
increased risks of sepsis and fluid sequestration and difficulties in dosing drugs metabolised 
by the liver, such as certain antibiotics like erythromycin and metronidazole. Severe liver 
injury may be irreversible and can also lead to a systemic inflammatory response and 
disseminated intravascular coagulation leading to mulitorgan dysfunction then multiorgan 
failure, with a mortality of 80-100% when three or more organs have failed. Livers with 
abnormal parenchyma, particularly steatosis and cirrhosis, are more susceptible to IRI with 
greater risks of liver failure and other postoperative complications, including sepsis and 
multiorgan dysfunction (Selzner et al. 2001; Belghiti et al. 1999; Huguet et al. 1992; Koneru 
et al.1992; Nguyen et al. 2009). 
In liver transplantation, during procurement of the organ, there is a period of warm 
ischaemia. The graft is then perfused with and stored in cold preservation solution, typically 
University of Wisconsin solution. This period of organ ischaemia is cold ischaemia and is 
followed by a period of warm ischaemia when the graft is being transplanted into the 
recipient. So, in liver transplantation the IRI that occurs is composed of two separate periods 
of warm ischaemia and a longer period of cold ischaemia in between before reperfusion of 
the graft in the recipient. During implantation, when the graft is ambiently exposed to body 
temperature it is rewarming and the time period while the graft is in the donor body cavity 
until it is revascularised is the warm ischaemia time. The length of the cold ischaemia time is 
mainly determined by logistic factors, such as the distance, the facilities available and 
personnel (Totsuka 2002). The length of the warm ischaemia time is less variable. It depends 
mainly on the quality and anatomical configuration of the recipient vessels and to a lesser 
degree the experience of the surgeon. The anhepatic phase is the period of time from 
clamping of the recipient hepatic vessels to restoration of portal flow, which is closely related 
to the warm ischaemia time (Figure 1.1.1). Graft reperfusion comprises three phases. Initially 
the graft is flushed via the portal vein and washed out through the superior vena cava 
anastomosis which is unclamped. The second phase consists of inferior vena cava and portal 
vein unclamping. Finally the arterial anastomosis is formed and the native hepatic artery is 
unclamped to complete graft reperfusion.  
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Dysfunction of a liver transplant graft varies from a reversible dysfunction (initial poor 
function, IPF) to liver failure requiring urgent retransplantation (primary nonfunction, PNF). 
The lack of a clear definition and diagnostic criteria for PNF and IPF has hindered the 
evaluation of the pathogenesis of these entities and partly explains the wide range of 
incidences reported in the literature. PNF represents failure of the allograft to function 
following revascularisation with no discernible cause requiring urgent retransplantation for 
the patient to survive. Various criteria have been used to define IPF with no consensus, but 
most definitions use various combinations and cutoffs for deranged serum liver enzymes, 
coagulopathy and bile output in the early postoperative period typically within the first 7 days 
(Ploeg 1993; Gonzalez 1994; Heise M 2003). A major risk factor for PNF and IPF of a graft 
is the cold ischaemia time, especially if it is longer than 13 hours (Burroughs AK 2006). 
There is evidence that the warm ischaemia time is also a risk factor if it is longer than 45 
minutes and the risk is synergistic with a cold ischaemia time of greater than 12 hours for 
PNF and IPF of a graft (Totsuka 2004). An anhepatic phase of longer than 100 minutes is 
associated with increased IPF and PNF, which is associated with increased one year mortality 
(Ijjtsma 2009).  
The overall incidence of PNF is 1.7-7.6% with the higher rates seen with donation after 
cardiac death (Nguyen et al. 2009). Where patients have received an allograft considered to 
have severe IRI the incidence of PNF is 41% (Rosen et al. 1998). PNF is an indication for 
super urgent retransplantation, so there is a clear need to understand the mechanisms that 
underpin liver IRI to guide therapeutic developments. Suboptimal grafts are particularly 
susceptible to IRI, where grafts with severe steatosis have high rates of PNF (Behrns et al. 
1998; Huguet et al. 1994). These complications are associated with increased length of ICU 
stay, with each extra day in ICU following a liver transplant costing on average £1800 
(Foxton 2010). There is some evidence that the severity of IRI is associated with acute 
rejection and Hepatitis C recurrence (Baron et al. 2000) in an allograft.
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The incidence of biliary complications following hepatic resection and transplantation 
surgery is anywhere between 10-15%, with bile leaks and biliary strictures being the most 
common (Eghtesad 2005, Mehrabi 2008). Anastomotic leaks occur early in the postoperative 
course and strictures tend to be late complications. Strictures can be classified as anastomotic 
and non-anastomotic. Anastomotic strictures are usually related to surgical problems and 
fibrous healing of the anastomosis. The most common cause of nonanastomotic stricture is 
ischaemia of the biliary epithelium caused by impaired arterial blood flow, hepatic artery 
thrombosis and ischaemia reperfusion injury (Sanchez-Urdazpal 1992, Buis 2006). 
Liver IRI can occur following prolonged periods of shock where there has been initial 
inadequate resuscitation or delayed resuscitation. This can occur both in haemorrhagic shock 
(Raddatz 2006) and in septic shock (Rushing Annals of Surgery 2008). This can lead to 
multiorgan dysfunction syndrome with an increased mortality. The mechanisms for this are 
not well understood, but a greater understanding of this phenomenon offers the possibility of 
pharmacologically modifying the response and improving the outcome. In the context of 
septic shock, the molecular mechanisms are multifactorial with many parallel pathways so it 
may  be  that  there  will  never  be  a  “magic  bullet”  for  sepsis  related  liver  injury  and  the  focus  is  
on first principles of basic resuscitation,  early appropriate antibiotics and source control. 
1.1.3. Methods of Assessment of Liver IRI  
The extent of liver injury in IRI is normally measured by raised levels of serum liver 
enzymes, most commonly aspartate transaminase (AST), alanine transaminase (ALT), lactate 
dehydrogenase (LDH) and/or serum glutamic-oxaloacetic transaminase (sGOT). There are 
other conditions that may raise these markers such as intrinsic liver disease, biliary conditions 
and direct liver trauma and liver sepsis. Other serum markers have been used in research to 
assess  liver  IRI,  such  as  serum  and  liver  tissue  cytokines  TNFα,  IFNγ  and  tissue  markers  of  
apoptosis, such as Bcl2 and caspase3 but these are not validated measures clinically and are 
still very expensive.  
Liver IRI is demonstrated histologically. The Suzuki classification, with or without 
modifications, is the most widely used in liver IRI (Suzuki et al. 1993). In this classification 
sinusoidal congestion, hepatocyte necrosis and ballooning degeneration are graded 0 to 5. No 
necrosis, congestion/centrilobular ballooning is given a score of 0 whereas severe 
congestion/ballooning degeneration, as well as >60 % lobular necrosis is given a score of 5. 
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Other classification systems have been used based on hepatocyte changes, extent of necrosis, 
haemorrhage and neutrophil infiltration (Saidi, Chang 2007).  
By definition liver IR injury involves a derangement of liver microcirculation. This has been 
demonstrated physiologically in a number of ways, including intravital fluorescence 
microscopy, thermodiffusion and surface laser Doppler flowmetry (Klar et al. 1997 and 1999; 
Koti et al. 2002; Vajdova et al. 2004; Tapuria et al. 2008). Surface Doppler probes placed on 
the liver surface can be used to assess the liver microcirculation. In the clinical context its use 
is currently limited to the intraoperative phase, and therefore the very early phase, of liver 
IRI. One group has used a large animal model of liver transplantation to validate the use 
dynamic functional MRI (dMRI) to assess liver microcirculation as measurements with dMRI 
correlated well with laser Doppler flow and thermodillution measurements (Zapletal et al. 
2009). This offers the possibility of noninvasively assessing liver microcirculation clinically 
postoperatively, but its use has yet to be studied clinically.  
Overall currently the best way of assessing liver IRI and its severity is by having an overall 
picture based on a clinical history with evidence, such as patient deterioration, failure to 
progress and right upper quadrant pain/tenderness especially with evidence of jaundice, 
deranged liver function tests and histological evidence of liver injury. 
 
1.1.4. Conclusions 
Liver IRI is a major clinical problem in hepatic resection surgery, transplantation and shock 
states. It is associated with increased morbidity and mortality. The diagnosis of liver IRI as a 
cause of patient deterioration is not straightforward, as there are often multiple factors 
contributing and depends on a combination of clinical findings and various investigations.  
With the advances in immunosuppression that have improved long term survival of 
allografts, acute postoperative complications in liver surgery still pose an important problem 
with IRI being directly or indirectly the underlying pathophysiology in many of these cases. 
This type of injury is more severe in marginal grafts. In an era where demand greatly 
outstrips supply, there is a greater pressure to use more marginal grafts from extended criteria 
donors. An understanding of the pathophysiology and molecular mechanisms of liver IRI is 
of great clinical importance, as it will help lead to interventions that reduce this major cause 
of morbidity and mortality in patients. 
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1.2. Mechanisms of Ischaemia Reperfusion Injury (IRI) 
 
We have seen that ischemia reperfusion injury is a major obstacle in liver resection and liver 
transplantation surgery. Prolonged organ ischemia is characterised by lack of tissue 
oxygenation and depletion of tissue ATP with a transition to activation of anaerobic 
metabolic pathways, which cannot maintain cellular function for prolonged periods 
ultimately leading to cell death. Restoration of blood flow is necessary to restore cellular 
function, but paradoxically reperfusion can initiate a cascade of pathways that cause further 
cellular injury after prolonged ischaemia. Understanding the mechanisms of liver IRI and 
developing strategies to counteract this injury will therefore reduce acute complications in 
hepatic resection and transplantation, as well as expanding the potential pool of usable donor 
grafts.  
 
The initial liver injury is initiated by reactive oxygen species (ROS) which cause direct 
cellular injury and also activate a cascade of mediators leading to microvascular changes, 
increased apoptosis and acute inflammatory changes with increased necrosis. Not all 
pathways activated are injurous and some adaptive pathways are activated during reperfusion 
that dampen the reperfusion injury. Classically two phases of liver injury have been 
described, an early phase of injury (<6 hours), characterised by Kupffer cell and NKT cell 
activation, release of proinflammatory cytokines and generation of ROS, and a late phase 
(>12 hours) characterised by neutrophil infiltration and further release of cytokines. In 
reality, this is a somewhat artificial distinction, as liver injury occurs as a continuum during 
reperfusion where pathways are activated at various often overlapping time points.  
 
1.2.1 Liver Anatomy and Physiology 
The liver is the largest visceral organ in the body. It has a large number of functions. It is 
important in carbohydrate metabolism and glycogen storage, protein and lipid metabolism. 
The liver synthesizes a number of proteins, including albumin. It produces coagulation 
factors II, VII, IX and X and Protein C and S. The liver stores Vitamins A, D and K. The 
liver breaks down a large number of substances, including hormones such as insulin and 
drugs such as erythromycin. Red blood cells are broken down in the liver and the biliverdin 
released is converted to bilirubin, which is excreted by the liver in bile. The liver forms part 
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of the reticuloendothelial system, containing many immunologically active cells that process 
and present antigen arriving from the portal circulation. 
 
In relation to IRI, it is important to have an understanding of the basic macroscopic and 
microscopic circulation of the liver. It receives 75 % of its blood supply from the 
deoxygenated portal circulation draining gut and other abdominal viscera and the other 25% 
from the hepatic artery. The oxygen delivery is 50% from the hepatic artery and the other 
50% from the portal vein. Occlusion of either portal vein or hepatic artery for a given time 
results in equivalent liver ischaemia. The blood from the portal vein and hepatic artery enters 
the liver lobes as left and right hepatic artery and the corresponding portal vein branches and 
drains the liver lobules through the sinusoids which drain into the central hepatic venules and 
eventually back to the inferior vena cava via the hepatic veins, which are normally three in 
number (Fig1.2.1). Sinusoidal endothelial cells (SEC or endothelial cell) line the sinusoids. 
The Space of Disse which drains bile to bile ductules separates hepatocytes from SECs. 
Kupffer cells lie within the sinusoids (Fig 1.2.1). The hepatocytes, SECs and Kupffer cells 
are the three liver cell types that are central to liver IRI.
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1.2.2. Liver Ischaemia Reperfusion Models 
Liver ischaemia reperfusion injury (IRI) has been demonstrated in different animal models 
with the various endpoints discussed (See 1.1.3). The models studied have used either large 
animals such as pigs or canine or small animals such as rats or mice.  Large animal models 
can be used to replicate surgical procedures and anaesthetic conditions that occur in liver 
resection surgery and transplantation in humans more closely than small animal models and 
therefore act as a good indicator of the pathophysiological insults that occur in humans. 
Experiments on large animals however are very costly, labour and time intensive. Hence, 
small animal studies have usually been used to develop models of liver IRI and probe and 
study molecular mechanisms underlying it and accounts for the vast majority of our 
understanding of liver IRI. 
A wide range of transgenic animals has been generated for mice. For reasons that are not 
fully understood, transgenic large animals are difficult to generate and rarely survive to term. 
Therefore, few are available. Transgenic mice, particularly genetic knockout models, have 
become a powerful tool at elucidating mechanisms of liver ischaemia reperfusion injury and 
are complementary to pharmacological studies and I will focus on mechanistic insights 
derived from transgenic knockout models of liver ischaemia reperfusion injury. This is 
because there is very specific targeted disruption of the protein at the genetic level rather than 
disruption  that  is  not  necessarily  as  specific  as  maintained  when  “specific”  pharmacological  
inhibitors or stimulants of the same protein are used.  Where there are discrepancies in results 
with knockout models or particular gene knockouts have not as yet been used to study liver 
IRI, large animal models, such as pig or canine models, of liver IRI have provided 
mechanistic insights into what is likely to occur physiologically in human liver IRI.  
The animal ischaemia reperfusion (IR) models studied have used global or partial hepatic 
ischaemia followed by reperfusion with or without liver resection only or liver 
transplantation. Global hepatic ischaemia results in more severe liver IRI and replicates the 
conditions during major liver resections and liver transplantation. This has been demonstrated 
in large animal models with warm ischaemia time (WIT) of up to 2 hours using passive 
bypass during ischaemia (Uhlmann et al. 2003,), although most studies used a WIT of around 
30 minutes without bypass, and cold ischaemia times up to 16 hours (Uhlmann et al. 2006; 
Brockmann et al. 2005; Qing et al. 2005). Similar results have been shown in a large number 
of small animal studies using global hepatic ischaemia with warm ischaemia times of up to 
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60 minutes is tolerated in rats and up to 30 minutes in mice (Shinohara et al. 1990; Minor et 
al. 1992; Suzuki et al. 1997; Shimamura et al. 2005). Partial hepatic ischaemia prevents 
splanchnic congestion that leads to gut oedema, therefore allowing decompression of the 
portal venous flow through perfused liver lobes. This in theory more specifically probes the 
pathophysiological mechanisms of liver IRI without interactions from effects on the gut 
influencing results, as well as replicating conditions in partial liver resection surgery. The 
animals tolerate longer periods of partial hepatic ischaemia and the liver IRI is less severe 
than for the equivalent global hepatic ischaemia times. This has been demonstrated in large 
animal models with ischaemia times of 1 to 2 hours and reperfusion of 5 hours to 4 days 
(Helling et al. 1999; Kannerup et al. 2010). Similar results have been demonstrated by the 
large number small animal studies of partial liver ischaemia reperfusion with ischaemia times 
of up to 2 hours in rats and 1 hour in mice (Metzger et al. 1988; Caldwell et al. 2005). The 
small animals studies of global and partial hepatic IR will be discussed in the subsequent 
sections with reference to mechanisms of IRI focusing on transgenic mouse models. 
 
1.2.3. Generation of a Genetic Knockout Organism 
Evans and Kaufman (Evans et al. 1981) and Martin (Martin et al. 1981) separately described 
the growth and maintenance of euploid cells in culture obtained from normal mouse embryos 
that had pluripotent potential, subsequently known as embryonic stem cells (ES cells). These 
cells were shown to be capable of giving rise to germline chimera after microinjection into 
blastocysts (Bradley et al. 1984). Thus, normal diploid ES cells could be grown in culture for 
multiple passages that could still contribute to normal development. The ES cells were also 
shown to form the germline with high frequency (germline competence). The haploid 
genomes of these cells were transmitted to the next generation. This set the stage for the 
introduction of mutations in these cells to produce mice with a targeted alteration in its 
genome. 
In an elegant series of papers using mammalian cell lines (Lin et al. 1985; Smithies et al. 
1985; Thomas et al. 1986), based primarily on prior work in Saccharomyces cerrivisae (a 
species of budding yeast), it became clear that cloned DNA could be precisely altered in 
vitro, and when introduced into cells via a number of methods (infection, transfection vector) 
would homologously recombine with the resident gene and introduce the desired mutation at 
that site in the genome.  Homologous recombination in this context is a process of genetic 
recombination that occurs between similar sequences of DNA during mitosis or repair of 
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damage to DNA sequences. In higher eukaryotes (Drosiphilia and mouse), unlike in lower 
eukaryotes (such as yeast), the frequency of homologous recombination occurs at a low rate. 
This is improved by the use of the combination of positive and negative selection. In positive 
selection, these rare events of homologous recombination are selected for by introduction of 
genes conveying resistance to otherwise toxic metabolites, such as neomycin. This method is 
frequently used to mutate the gene of interest. The frequency of these rare events can further 
be increased by negative selection, most commonly performed by using a thymidine kinase 
(TK) gene flanking the targeting vector. ES cell clones which retain the TK gene 
(nonhomologous recombination) do not survive the addition of gancyclovir (or homologues) 
to the media due to the accumulation of toxic nucleosides, whereas cell clones which have 
undergone an authentic recombination lose the TK gene. This combined strategy is known as 
positive-negative selection (Mansour et al. 1988) and routinely increases the targeting 
frequency by at least an order of magnitude. 
Once these mutated ES cells are isolated as a pure clone, they can be introduced into the 
blastocoele cavity of a normal embryo, where they participate in the development of all 
tissues and result in the production of chimeras (usually assessed at birth by acquisition of the 
dominant coat color phenotype Agouti). In matings of these chimeric mice with normal wild 
type mice, if the ES cells have contributed to formation of germ cells in the chimeras, half the 
offspring are heterozygotes for the mutated gene. Mating heterozygotes, each carrying a 
mutated copy of the gene of interest (detected by analysis of the isolated DNA), produces 
homozygotes in a quarter of the offspring. If these homozygotes have a targeted gene deletion 
they are knockout mice for that gene, and hence the protein it encodes.  This whole process is 
known as gene targeting and is currently the best way of producing knockout organisms. 
Understanding the cellular and molecular mechanisms of liver IRI offer the possibility of 
minimising its debilitating effects in the clinical setting. The attraction of using genetic 
knockouts to study models of liver IRI is that knockouts can provide robust mechanistic 
insights, as the disruption is specific and complete at the genetic level rather than relying on 
pharmacological agents that act on proteins but may not be as specific as advertised. To this 
effect, genetic knockout models have been used to study liver IRI as will be discussed in 
sections 1.2.3 to 1.2.17. 
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1.2.4. Reactive Oxygen Species (ROS) 
Depletion of intracellular and extracellular ATP during ischaemia results in increased ATP 
degradation products, including adenosine, hypoxanthine and xanthine and a shift towards 
anaerobic metabolism. On reperfusion, initially the increase in oxygen delivery exceeds the 
rate at which cellular metabolism returns to aerobic pathways, that generates damaging free 
radicals (ROS). A wide variety of ROS are generated, the most widely implicated being 
superoxide, hydrogen peroxide and nitric oxide.  
There are thought to be three main pathways for the generation of ROS: conversion of 
xanthine dehydrogenase to xanthine oxidase during ischaemia, NADPH oxidase activation 
and uncoupling of the mitochondrial electron transport chain (Andrukhiv et al. 2006; 
Jaeschke et al. 1993). Although hepatocytes can directly produce ROS, physiologically 
Kupffer cells are thought to be the main source of ROS in the early stages of liver IRI with 
NKT cells generating ROS later and neutrophils being the main source in the very later stages 
(Andrukhiv et al. 2006; Jaeschke et al. 1993). The role of these various cells, NADPH 
oxidase and mitochondrial depolarisation have been supported by knockout animal models 
(Ozaki et al. 2000; Theruvath et al. 2008). No xanthine oxidase knockout studies have been 
used on liver IRI. These mice only survive up to 6 weeks and are runted.  Intriguingly, one 
study of XO deficient rats in intestinal IRI showed no role for XO. Another pathway for the 
generation of ROS is dependent on Fe2+ ,a byproduct of haem oxygenase-1 which is activated 
by IR injury, called the Haber-Weiss reaction. The first step of the catalytic cycle involves 
reduction of ferric ion to ferrous: 
 
Fe3+ +  •O2− →  Fe2+ + O2 
The second step is the Fenton reaction: 
Fe2+ + H2O2 →  Fe3+ + OH− +  •OH 
Net reaction: 
•O2
- + H2O2 →  •OH  +  OH- + O2 
 
1.2.5. Microcirculatory dysfunction 
Microcirculatory changes play an important part in hepatic IRI. Reduction in sinusoidal 
diameter and blood flow are among the earliest changes in reperfusion injury. This results 
from a combination of direct damage to sinusoidal endothelial cells (SECs) with ischaemia 
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and reperfusion, vasoconstriction mediated by vasoactive substances and expression of 
adhesion molecules with accumulation of platelets and leucocytes. 
Two of the key vasoactive substances that maintain sinusoidal vascular tone are endothelin-1 
(ET-1), a vasoconstrictor, and nitric oxide (NO), a vasodilator and inhibitor of platelet 
aggregation.  There appears to be a relative excess of ET-1 in the early stages of liver IRI.  
Large animal models of orthotopic liver transplantation using pigs have provided evidence 
that after reperfusion Kupffer cells are activated which leads to increased release of ET-1 
which binds to SEC and hepatocyte ET(A) receptor, thereby reducing hepatic micro and 
macroperfusion after ischaemia and during reperfusion with associated increased liver injury 
(Frankenberg et al. 2005; Uhlmann et al. 2006). The activation of this pathway is associated 
with increased expression of TNF , IL 6 and endothelial NOS (eNOS) (Frankenberg et al. 
2005; Uhlmann et al. 2006). Knockout models for ETB receptor or heterozygote knockout for 
endothelin-1 have not been studied in liver ischaemia reperfusion injury. Double knockouts 
of endothelin-1 (ET-1), ET-2 and ETA receptor are lethal pre- or perinatally. It has become 
apparent products of haem oxygenase, namely carbon monoxide (CO) and biliverdin, are 
likely play a role in reducing the severity of liver IRI in vivo at least partly by directly 
improving liver microcirculation (Katori et al. 2002 x2; Miyagi, Iwane et al. 2008). 
 
1.2.6. Cell injury and death 
Hepatocytes and SECs are the two main cell types that are injured in IRI. Hepatocytes are 
more sensitive to warm ischaemic injury (37oC), while SECs are more sensitive to cold 
ischaemia (4oC) found in cold preservation of donor liver grafts before transplantation. 
Physiologically, exclusive injury of one cell type is not found and there is evidence that both 
cell types have been injured directly in both cold and warm IRI by ROS. The SECs and 
Kupffer cells are actively involved in initiating and maintaining IRI, the former mainly 
through expression of adhesion molecules activating inflammatory pathways and the latter 
through antigen independent activation of CD4+ T cells. 
There has been debate about what the primary mode of cell death is in liver IRI: apoptosis or 
necrosis. Apoptosis is an energy dependent process, so in theory when there is greater 
depletion of ATP, necrosis should dominate. Also, necrosis takes longer to become apparent, 
normally more than 3 hours. This is challenging to show experimentally in vivo, as tissue 
ATP before and after reperfusion would need to be measured as well as the change in 
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metabolic state of the cell. Therefore, varying degrees of necrosis and apoptosis have been 
shown in the literature for given ischaemia reperfusion protocols.  
Different assays have been used to implicate apoptosis, including activation of various genes 
such as caspase-3 which is thought to be a specific indicator of apoptosis, and Bax. One 
isolated ex vivo perfused liver model using knockout of Bax showed reduced liver IRI (Table 
2), apoptosis and caspase-3 activation in the knockouts compared to the normal wild type 
livers (Ben-Ari et al. 2007). The TUNEL assay has been used to indicate apoptosis, but it 
now appears that it does not specifically distinguish between apoptosis and necrosis. Many of 
the same initiators and pathways are involved for both types of cell death, so there is much 
overlap. Some authors refer to the process as necro-apoptosis.  
 
1.2.7. Adhesion Molecules 
The adhesion to the hepatic sinusoidal endothelial cells and transmigration into liver tissue 
require sequential steps in which many molecules are involved. The selectin family (P- E- 
and L-selectin) of adhesion molecules is expressed by SECs early in reperfusion. They 
mediate loose or rolling adhesion of platelets and leucocytes. Knockout models indicate that 
there is an initial peak of P-selectin expression 20 to 30 minutes after reperfusion which is 
required for early IRI (Sawaya et al. 1999; Singh et al. 1999). Functionally, some groups 
have found that E-selectin expression, and not P-selectin, is required for IRI to occur (Young 
et al. 2001). This is followed by firmer adhesion of leucocytes on SECs by upregulation of 
integrins, such as Mac-1 and LFA-1, and intercellular adhesion molecules (VCAM-1 and 
ICAM-1), respectively (Table 1.2.1).  
 
1.2.8. Platelets 
Platelets and leucocytes begin to adhere to SECs within 5 minutes of reperfusion (Table 
1.2.1). Khandoga et al. used an ICAM-1 knockout model of liver IRI to show that the very 
early phase of IRI characterised by increased lipid peroxidation, apoptosis and reduced 
sinusoidal perfusion, depends on platelet rather than leucocyte adhesion, mediated by 
fibrinogen deposited on adhesion molecules: E-selectin, VCAM-1 and ICAM-1 on SECs 
(Khandoga et al. 2002). 
 
1.2.9. Neutrophils 
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Neutrophils are important cellular mediators of liver IRI after 6 hours of reperfusion (Hines 
et al. 2002; Kawachi et al. 2000). The neutrophil oxidative burst is the main source of 
reactive oxygen species in the later stages of IRI and contributes directly to necrosis and 
apoptosis. This has been supported by immunologically deficient knockout models of liver 
IRI (Shimamura et al. 2005; Ozaki et al. 2000). Neutrophil recruitment is mediated, at least in 
part, by MIP-2 binding to the chemokine receptor CXCR2 on neutrophils, supported by a 
study using a CXCR2 knockout model (Kuboki et al. 2009). Neutrophil transmigration within 
liver sinusoids occurs over fibronectin (Hamada et al. 2009). A complex mixture of 
substances including cytokines, chemokines and adhesion molecules produced by other 
leucocytes and various liver cell types coordinates these responses. These will be discussed 
further. 
 
1.2.10. CD4+ T cells: NKT cells and αβ  T cell receptor (TCR) T cell 
CD4+ T cells, but not B cells or CD8+ T cells  (Caldwell et al. 2005) or NK cells (Kuboki et 
al. 2009; Shimamura et al. 2005) are activated and recruited into liver sinusoids in liver IRI 
(Figure 1.2.2). They have a dual role either contributing to injury or reducing the extent of 
injury depending on the CD4+ subtype and mechanism of cellular activation (Table 3). The 
majority  of  CD4+  T  cells  can  be  subdivided  into  αβ  TCR  (the  most  common  subtype)  
expressing  cells,  γδ  TCR  expressing cells, NKT cells and regulatory T cells (Treg).  
NKT cells contribute to liver injury in the early stages from 1 hour of reperfusion onwards. 
This has been supported by immunologically deficient knockout models, such as nu/nu and 
CD1d knockout mice (Shimamura et al. 2005; Kuboki et al. 2009; Lappas et al. 2006). NKT 
cells are also thought to contribute to neutrophil activation mediated by cytokines they 
release, such as interferon gamma (Lappas et al. 2006). A study using T cell subtype specific 
knockouts  showed  Treg  cells  are  not  involved  in  IRI  and  γδ  TCR  T  cells  recruit  neutrophils  
but this does not affect the severity of IRI (Kuboki et al. 2009). 
There is a large body of evidence that CD4+ T cell activated in IRI is by antigen independent 
pathways (Huang et al. 2007). This is supported by knockout models, in which activation of 
the Toll-like receptor 4 (TLR 4) on Kupffer cells is most consistently implicated (Shen et al. 
2007). One knockout model showed that CD4+ T cell related liver IRI depended on 
costimulatory activation of the CD4 with the CD154 receptor on activated T cells (Shen et al. 
2002). There is emerging evidence that there are also antigen dependent pathways activated 
in liver IRI. One model using a knockout for a TCR specific for ovalbumin self antigen 
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showed reduced IRI in the knockout, indicating that a small subset of T cells sensitised to self 
antigen contribute directly to liver IRI at least up to 8 hours into reperfusion (Kuboki et al. 
2009). 
CD4+  T  cells  of  the  αβ  TCR  variety  are recruited into liver sinusoids within 1 hour of 
reperfusion. CD4+ T cell knockout models of liver IRI with adoptive transfer of functional 
CD4+ T cells into the knockout mice indicate that these cells are involved in neutrophil 
recruitment via cytokines such as interleukin 17 (IL 17) and MIP-2, but these T cells inhibit 
the neutrophil oxidative burst. Overall they reduce the extent of liver IRI both indirectly via 
cytokines they release affecting other leucocytes and directly acting on hepatocytes (Caldwell 
et al. 2005).  
Therefore, in summary NKT cells contribute directly to early liver IRI and indirectly to late 
IRI  by  recruiting  neutrophils.  αβ  TCR  CD4+  T  cells  are  activated  by  Kupffer  cells  by  an  
antigen independent mechanism, which recruits neutrophils into liver sinusoids, but these 
CD4+ T cells inhibit the neutrophil oxidative burst and overall reduce the severity of IRI. A 
small subset of CD4+ T cells activated by self antigen contribute to IRI. 
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Figure 1.2.2: Schematic diagram of cellular mechanisms of liver IRI within a liver sinusoid and the 
surrounding area containing hepatocytes. Initial sinusoidal perfusion failure from platelet plugging, 
then Kupffer cells activate CD4+T cells that activate NKT cell which cause SEC and hepatocyte 
injury, followed by neutrophil activation, adhesion and transmigration causing more cell injury. 
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TABLE 1.2.1: Summary of knockout models of liver ischemia reperfusion injury pertaining 
to reactive oxygen species, adenosine and cells involved in the injurious mechanisms 
Author/Yr Knockout 
model 
IR 
Protocol 
Outcome 
Measure 
Agent Adaptive 
Responses 
Injurous 
Responses 
Kuboki et al., 
2009 
OTII; TCR 
deficient 
70% I 90 
min/R 4,8h 
Histology; 
serum ALT; 
MPO 
antiCD1d Ab; anti 
NK1.1 Ab; anti CD25+ 
Ab 
 Antigen dependent 
CD4+ T cell activation 
via TCR and NKT cell 
activation increase IRI; 
 T cell recruit PMN 
but not affect  IRI 
Evans et al., 
2008 
ob/ob or double 
knockout of 
leptin and UCP2 
Total hepatic 
iscahemia 15 
min/R 1, 24h 
Histology; 
serum ALT; 
WB; liver ATP 
assay; lipid 
peroxidation 
  In steatotic livers of 
ob/ob mice only, UCP-2 
depletes liver ATP 
which increases IRI 1h 
onwards 
Hanschen et 
al., 2008 
IL6(-/-);  
CD4(-/-); 
TNFR1(-/-) 
Left lobe I 90 
min/R 30 
min, 2,3,4h 
Kupffer cell 
activity 
(fluorescent 
latex beads and 
IVM); IH; 
serum AST and 
ALT 
GdCl3 or glutathione to 
wild types (WT) only 
 Kupffer cells activation, 
ROS, IL6 and TNF 
increase SEC VAP-1 
expression and CD4+ 
Tcell sinusoidal 
recruitment which 
increase IRI. CD4+ T 
cells inhibit Kupffer cell 
phagocytic activity 
Kim et al., 
2008 
Adenosine A1 
receptor 
(A1AR)(-/-) 
70% I 
1h/R 24h 
Histology; ALT; 
IH; PCR; WB;  
CCPA (AIAR agonist); 
DPCPX (A1AR 
antagonist) 
Endogenous adenosine 
via A1AR reduces IRI 
Exogenous adenosine 
increase IRI not via 
A1AR 
Lappas et al., 
2006 
Rag1(-/-), 
i.e.lack mature 
lymphocytes 
A2AR(-/-); 
IFNγ(-/-) 
70% I 72 
min/R 2,24h 
Histology; 
serum ALT; 
intracellular 
IFNγ 
i.p. ATL146 (A2AR 
agonist); PK136 
(NK1.1 depletion); 
CD1d Ab (inhibit NKT 
cell); NKT cell 
adoptive transfer from 
WT,  A2AR  and  IFNγ  
KO to Rag1 KO 
Exogenous and 
endogenous adenosine 
acts through A2AR to 
reduce NKT cell 
recruitment 
NKT cell recruitment 
increases IRI through 
release  of  IFNγ  from  at  
least 2 h reperfusion 
onwards and increased 
neutrophil recruitment 
from at least 24h after 
reperfusion 
Caldwell et al., 
2005 
CD4 (-/-); B cell 
(-/-) 
70% I 90 
min/R 
1,2,4,8h 
Histology; 
serum ALT; 
MPO 
Adoptive transfer 
CD4+T cell to CD4(-/-
); Anti-IL17 Ab 
CD4+ T cell only 1-4 h 
after reperfusion secrete 
IL17 increasing PMN 
infiltration, but 
inhibiting their 
oxidative burst 
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Khandoga et 
al., 2002 
ICAM(-/-) Left lobe I 90 
min/R 20 min 
Serum AST and 
ALT; IH; IVM 
caspase-3 assay;  
Anti-fibronectin Ab  Platelets bind 
fibronectin deposited on 
ICAM-1 on SECs 
Shen et al., 
2002 
nu/nu; CD154(-
/-) 
70% I 90 
min/R 4h 
Serum ALT; 
histology; MPO; 
WB 
Anti-CD154 Ab to 
WT; adoptive transfer 
T cell to KO or Ab  
group 
IRI induces HO-1 
protein  
CD4-CD154 T cell 
costimulation in IRI 
Wyllie et al., 
2002 
Nramp(-/-) 70%I 45 
min/R 30,60 
min 
Plasma GOT 
and  TNFα; 
histology; WB; 
IH; EMSA  
 HO-1 expressed  in this 
model is protective in 
IRI 
Macrophage activation  
after reperfusion 
increases TNFα  release  
and  NFκβ  activity 
Young et al., 
2001 
P-selectin/ 
ICAM-1 double 
KO  
70% I 90 
min/R 
1.5,3,6h 
Serum ALT; 
histology 
  P-selectin and ICAM-1 
do affect the severity of 
IRI  upto 6 h 
reperfusion, midzonal 
PMN infiltration 
Ozaki et al., 
2000 
gp91 phox 
component of 
phagocyte 
NADPH 
oxidase(-/-) 
70% I 60 
min/R 
5,8,24h+/- i.v. 
injection 3 
days preop of 
adenovirus 
Serum ALT; 
histology (H&E; 
ELISA for DNA 
histone 
fragments); 
TUNEL; IH; 
WB; assays for 
lipid 
peroxidation, 
hydrogen 
peroxide and 
superoxide; 
EMSA  (NFκβ) 
 
Replication deficient 
adenovirus encoding 
Rac1  (control:  Adβgal) 
Rac1 is activated in IRI 
and is protective 
Liver tissue releases 
ROS within 5 min of 
reperfusion. PMN 
recruited 8h onwards, 
associated with 
increased lipid 
peroxidaion, necro-
apoptosis.  NFκβ  DNA  
binding is associated 
with increased IRI. 
NADPH oxidase 
regulated by Rac1 small 
GTP binding protein is 
a source of ROS in IRI 
Sawaya et al., 
1999 
P-selectin(-/-) Left lobe I 30 
min/R 15, 30, 
60 120 min 
Serum AST, 
ALT, LDH; 
histology; IVM 
Radiolabelled Anti P-
selectin Ab 
 P selectin on SECs 
increases rolling/ 
adherent leucocytes 
(peak 30 min R) 
KO: transgenic knockout; I: ischemia; R: reperfusion; IR: ischemia reperfusion; IRI: ischemia reperfusion injury; ROS: 
reactive oxygen species; ATP: adenosine triphosphate; IH: Immunohistochemistry; H&E: haemotoxylin and eosin; WB: 
Western blot; MPO: Myeloperoxidase assay; PCR: Polymerase chain reaction; ELISA: Enzyme labelled immunosorbent 
assay; EMSA: Electrophoretic mobility shift assay; AST: Aspartate transaminase; ALT: Alanine transaminase; LDH; lactate 
dehydrogenase; GOT: glutamic oxaloacetic transaminase; NADPH; nicotinamide adenine dinucleotide phosphate; IR: 
ischemia reperfusion; IVM: intravital microscopy; THV: terminal hepatic venule; A2AR: adenosine (subtype 2A) receptor; 
Nramp: natural resistance associated macrophage protein; PMN: polymorphonuclear cell; NKT: natural killer T cell; NK: 
natural killer cell; IFN: interferon; Ab: antibody; TNF: tumour necrosis factor; TNFR1: tumour necrosis factor receptor 
(subtype 1); TCR: T cell receptor; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling (assay for cell 
death); IL: interleukin; ICAM: intercellular adhesion molecule; VAP: vascular adhesion protein 
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1.2.11. Cytokines and Chemokines 
The interplay between cytokines and chemokines in liver IRI is not fully understood. The 
most  extensively  studied  cytokines  are  TNFα,  interferon  (IFN)  β,  IFN  γ  and  IL6. 
TNFα has a directly injurous effect on ischaemic but not normal liver tissue (Teoh et al. 
2004).  Release  of  TNFα  is  stimulated  by  a  cytokine  cascade  involving  activation of interferon 
regulatory factor (Tsung et al. 2006). Antigen independent macrophage/Kupffer cell TLR 4 
activation  stimulates  TNFα  release  (Shen  et  al.  2005,  2007).  The  effects  of  TNFα  are  
mediated by binding to its receptor TNFR1 leading to increased apoptosis (Rudiger et al. 
2002; Tian et al. 2006) and increased CD4+ T cell sinusoidal recruitment (Hanschen et al. 
2008). One knockout model of mouse liver transplantation showed the deleterious effects of 
TNFα  are  mediated  by  TNFR  outside  the  liver, most likely infiltrating leucocytes, but TNFR 
on liver cells appear to reduce IRI in this model (Table 1.2.2). The possible downstream 
pathways mediating this dual role will be discussed (Figure 1.2.3). 
Interferon  beta  (IFN  β) has emerged as a cytokine that appears to be involved throughout 
the reperfusion period in liver IRI, substantiated by work using knockout mice (Fig 1.2.2 
Zhai  et  al.  2004).  The  damaging  effects  of  IFN  β  are  mediated  by  binding  to  the  interferon  
receptor subtype IFN AR (Type 1) (Zhai et al. 2008) which upregulates interferon regulatory 
element 1 (IRE-1) (Figure 1.2.3) (Tsung et al. 2006). Knockout models support other studies 
in that IFN  γ produced by NKT cells contribute to liver IRI from early on in reperfusion 
onwards (Shen et al. 2007; Tsung et al. 2006; Hamada et al. 2008; Tsuchihashi et al. 2006). 
Activation  of  innate  immune  pathways  via  TLR  4  stimulate  release  of  IFN  β  and  IFNγ  in  
liver IRI, confirmed by TLR 4 knockout models (Shen et al. 2007). 
Some cytokines released during liver IRI appear to reduce the severity of injury. The best 
evidence for this from knockout studies is for IL6 (Camargo et al. 1997). There was worse 
IRI in livers of IL6 knockout mice than wild type mice, which was reversed by 
administration of recombinant IL6 to the knockout mice before ischaemia.  
Chemokines (CXCL) are very small molecules, which are highly localised and form 
concentration gradients that guide leucocyte chemotaxis. One knockout model of CXCL10 
found showed that this chemokine contributed to liver IRI  (Figure 1.2.3 and Table 1.2.2) 
from 1 hour reperfusion onwards with associated activation of neutrophils, Kupffer cells and 
increased  TNF  α  and  IL  1β  release  (Zhai  et  al.  2008).  A  study  using  knockouts  of  chemokine  
receptor 2 (CXR 2) showed CXCR 2 activation contributes to liver IRI and neutrophil 
recruitment (Kuboki et al. 2008). 
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TABLE 1.2.2: Cytokine, chemokine and toll like receptor knockout models of liver IRI 
Author/Yr Knockout model IR 
Protocol 
Outcome 
Measure 
Adaptive 
Responses 
Injurous Responses 
Kuboki et al., 
2008 
CXCR2 70% I 90 
min/R 
12,24,48, 
96h 
Histology; MPO; 
serum ALT, TNF; 
WB: EMSA; 
CXCR2 activates 
STAT3 hepatocyte 
proproliferative 
pathway 
CXCR2 increases neutrophil 
recruitment and IRI. NF 
activity reduced in IRI 
Zhai et al., 
2008 
CXCL10(-/-) 70% I 90 
min/R 
2,4,8h 
Histology; serum 
ALT; IH; quantitative 
RCR; WB 
 CXCL10 increases TNF, 
IL6, IL1, iNOS, PMN and 
Kupffer cell activation  
Zhai et al., 
2008 
IFNAR type1 (-/-); 
IFNAR type 2 (-/-) 
70% I 90 
min/R 6h 
Histology; 
quantitative PCR 
 IFN (not IFN) mediates IRI 
by binding to IFNAR type 1 
Tsung et al., 
2006 
Interferon regulatory 
factor-1(IRF-1)(-/-) 
+/-Adenovirus IRF-1 
vector 
 
70% I 60 
min/R 
1,3,6,12h 
Histology;serum 
ALT; WB;PCR 
 IFNγ,  IFNβ,  TNFα,  IL1β  all  
activate IRF-1 which increase 
Jnk (not p38 MAPK) and 
TNFα  and  iNOS  expression  
in IRI 
Shen et al., 
2005 
TLR4(-/-); TLR2(-/-
)+/-SnPP (inhibit HO-
1)  
70% I 90 
min/R 6h 
Histology; serum 
ALT; MPO; WB; 
PCR 
HO-1 is expressed 
which inhibits TLR4 
TLR4 activation increases 
TNFα  expression  associated  
with increased IRI 
Teoh et al., 
2004 
TNFα(-/-) +/- low or 
high  dose  TNFα  i.p. 
70%I 90 
min/R 
2,4,24h 
Serum ALT and 
TNFα;;  IH;;  WB  
EMSA(NFκβ) 
 TNFα  injurous  to  ischaemic  
liver,  increased  NFκβ  activity 
Kato et al., 
2002 
IL1R(-/-) 70%I 90 
min/R 
1,2,4,8,16,2
4h 
Serum ALT, 
IL1β,TNFα  and  MIP-
2; Histology (PMN 
score); MPO; EMSA  
 IL1R not involved in IRI 
Rudiger and 
Clavien, 2002 
TNFR(-/-); Fas(-/-); 
FasL(-/-) +/-
Pentoxyphylline 
70% I 75 
min/R 3h 
Serum AST; TUNEL; 
caspase-3 
assay;ELISA; WB 
 
 TNFα  binds  to  TNFR1  which  
increases apoptosis in IRI. 
Fas and FasL not involved in 
this model 
Camargo et 
al., 1997 
IL6(-/-)+/- 
recombinant IL6 
Median 
lobe (45%) 
I 90 min/R 
30,60,90, 
120 min 
Serum AST and ALT; 
histology; PCR 
IL6 released in IRI is 
protective 
TNFα  expression  during  
reperfusion is associated with 
worse IRI 
IH: Immunohistochemistry; WB: Western blot; MPO: Myeloperoxidase assay; PCR: Polymerase chain reaction; ELISA: 
Enzyme labelled immunosobert assay; EMSA: Electrophoretic mobility shift assay; IH: immunohistochemistry; ALT: 
Alanine transaminase; I: ischemia; R: reperfusion; IR: ischemia reperfusion; IRI: ischemia reperfusion injury; IFN: 
interferon; TNF: tumour necrosis factor; TNFR1: tumour necrosis factor receptor (subtype 1); TLR: Toll-like receptor 
(subtype); TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling (assay for cell death); IL: interleukin; 
CXCR: chemokine receptor; CXCL: chemokine ligand (subtype) NF: nuclear factor; i.p.: intraperitoneal 
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1.2.12. Matrix metalloproteinase-9 (MMP-9) 
MMP-9 is a zinc dependent secreted gelatinase which catalyses degradation of type IV 
collagen and gelatin. MMP-9 knockout models of liver IRI have shown increased expression 
of MMP-9 on macrophages and neutrophils occurs during reperfusion (Table 1.2.3) which 
increases neutrophil transmigration over fibronectin  in  liver  sinusoids  and  increases  TNF  α  
and  interferon  γ  secretion  and  CD4+  T  cell  activation  by  mechanisms  that  remain  to  be  
elucidated. This leads to increased liver cell apoptosis and necrosis (Hamada et al. 2009; 
Hanschen et al. 2008). 
 
1.2.13. Nitric Oxide Synthase  
Nitric oxide synthase (NOS) catalyses formation of nitric oxide (NO) from L-arginine. NO is 
a versatile molecule which is vasoactive, is involved in activating molecular signalling 
pathways in cell survival, has immunological effects as well as directly injurous effects in 
high levels as a free radical itself. There are three isoforms of NOS: constitutive calcium 
(Ca2+) dependent forms which are endothelial NOS (eNOS) and neuronal NOS (nNOS), and 
an inducible calcium independent form, namely inducible NOS (iNOS). Only eNOS and 
iNOS are expressed in liver. Double knockouts of eNOS (eNOS-/-) and iNOS (iNOS-/-) have 
been generated. They have complete genetic knockout of eNOS or iNOS respectively, so the 
animal with that gene knocked out does not express the protein in any cell.  The animals are 
viable and have been used in validated liver IR models to study IRI in vivo. The IR protocols 
in most studies involve using partial hepatic ischaemia of between 45 minutes and 1 hour and 
reperfusion of between 1 to 6 hours (Hines et al 2002; Lee et al. 2001). 
Most studies agree that eNOS is upregulated in liver IRI and this reduces the severity of IRI. 
This is confirmed by eNOS knockout models of IRI (Table 1.2.3), where eNOS expression is 
related to reduced liver necrosis, apoptosis, leucocyte infiltration and increasing liver 
sinusoidal diameter and blood flow compared to control normal mice (Hines et al. 2002; 
Kawachi et al. 2000; Lee et al. 2001; Theruvath et al. 2006). 
The role of iNOS is more controversial (Table 1.2.3) with different studies showing either no 
effect, iNOS contributing to IRI or iNOS reducing IRI. Some knockout models of iNOS 
show no role for iNOS in liver IRI, although apparently similar IR protocols and liver IRI 
models were used in the different studies (Kawachi et al. 2000; Hines et al. 2001; Khandoga 
et al. 2002). One knockout study of iNOS showed in the liver IRI model used that iNOS was 
protective which was at least partly mediated by activation of iNOS by eNOS (Hines et al. 
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2002). Yet another set of knockout studies conclude iNOS contributes to IRI. Hamada et al. 
used separate iNOS and matrix metalloproteinase-9 (MMP-9) knockout mice to show in their 
model of liver IRI that iNOS is upregulated in macrophages which increases IFN  γ  release  
and NO which increases MMP-9 expression on the macrophages and neutrophils. This 
signalling cascade contributes to increased liver IRI. Hines et al. (2001) used iNOS 
knockouts in a partial (70%) liver IR model to show increased IRI in iNOS-/- mice compared 
to normal mice, but no iNOS mRNA was detectable in normal mice nor any effect of an 
iNOS inhibitor. This suggests that genetic compensation occurs.  
Large animal models of warm liver ischaemia reperfusion and an orthotopic liver 
transplantation using pigs have found that there is increased iNOS expression, highest in 
Kupffer cells and neutrophils in the centrilobular region, with associated higher levels of 
serum nitrite/nitrate, reduced capillary perfusion with more thrombi and ultimately increased 
liver injury and increased mortality (Kimura et al. 2003; Meguro et al. 2002,2003). 
These discrepancies in the role of iNOS in liver IRI are likely to reflect differences in the 
experimental protocol and some genetic compensation in iNOS knockout mice. The overall 
impression from the literature is that eNOS and iNOS are both induced during liver IRI from 
1hour reperfusion onwards (for mRNA and 2 hours reperfusion onwards for protein) and 
eNOS reduces injury. Low levels of iNOS induction are probably protective while high 
expression of iNOS contributes to increased injury and the overall effect of iNOS 
physiologically most likely depends on how ischaemia and reperfusion is produced. 
 
1.2.14. Haem Oxygenase-1 
 
Haem oxygenase-1 (HO-1 or heat shock protein 32, hsp 32) is the inducible isoform of haem 
oxygenase, the constitutive isoform being HO-2. This enzyme catalyses the formation of 
carbon monoxide (CO), biliverdin and Fe2+ from haem degradation. HO-1 has been 
implicated as having a protective role in IRI through CO and biliverdin associated with 
microcirculatory beneficial effects and reduced apoptosis and necrosis (Katori et al. 2002). 
HO-1 is typically expressed three or more hours after liver reperfusion (Shen et al. 2005; Su e 
al. 2006). The protective effects of HO-1 are supported by knockout models of IRI (Table 5) 
(Shen et al. 2005; Tsuchihashi et al. 2006).  One knockout model demonstrated that targeted 
deletion of the HO-1 gene (Hmox-1-/-) resulted in aberrant Kupffer cell differentiation and 
increased susceptibility to ischaemia reperfusion insults (Devey et al. 2009 ).  
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TABLE 1.2.3: NOS, hsp/Hmox-1, MMP knockout models of liver IRI. 
Author/Yr Knockout 
model 
IR Protocol Outcome 
Measure 
Adaptive Responses Injurous Responses 
Hamada et 
al., 2009 
iNOS(-/-); 
MMP-9(-/-) +/- 
ONO-1714 
(iNOS inhibitor) 
or NO donor 
(DETA 
NONOate) 
70% I 90 min/R 
3,6,24h 
Histology; serum 
ALT, NO2-/NO3-
MPO activity; IH; 
PCR, Western 
Blot (WB); MMP-
9 assays; PMN 
migration assay 
 Increased  macrophage 
iNOS producing NO 
increases PMN MMP-9 and 
PMN transmigration over 
fibronectin 
Hamada et 
al., 2008 
MMP-9 (-/-) 70% I 90 min/R 
6,24h +/-Anti 
MMP-2/9 
inhibitor 
Histology; serum 
and GOT; MPO; 
IH; PCR 
 IRI: MMP-9 (not MMP-2) 
increase TNF, IFN, IL2, 
IL6 and increase PMN and 
CD4+ T cell recruitment  
Theruvath et 
al., 2006 
eNOS(-/-) Donor(WT/KO) 
to WT recipient; 
organ stored 
18h, 4oC,UWS 
Histology; serum 
ALT; IVM; 
TUNEL; IH 
(macrophage 
infiltration) 
eNOS activation reduces 
necro-apoptosis, inhibits 
macrophage infiltration, 
increased sinusoidal 
diameter and flow 
 
Tsuchiashi et 
al., 2006 
Hmox-1(+/-); 
Hmox-1(-/-
);CoPP (induces 
HO-1) in WT 
70% I 90 min/R 
6h 
Histology; serum 
GOT; MPO; 
TUNEL; PCR; 
WB 
HO-1 upregulated which 
inhibits expression of 
cytokines  TNFα  and  IFNγ 
TNFα  and  IFNγ  expression 
increased overall in IRI 
associated with increased 
apoptosis and necrosis 
Hines et al., 
2002 
eNOS (-/-); 
iNOS (-/-) 
70% I 45 min/R 
1,3h 
Serum ALT; 
histology; PCR 
IRI reduced by eNOS 
(inhibits  TNFα);;  and  iNOS   
Liver IRI in eNOS (-/-) and 
iNOS (-/-) 
Lee et al., 
2001 
eNOS(-/-); 
iNOS(-/-) 
70% I 1h/R 
1,3,6h 
Serum ALT, 
AST;  
eNOS activated during IRI 
is protective 
Increased iNOS mRNA 
from 3 h with increased IRI 
Hines et al., 
2001 
iNOS(-/-)  70% I 45 min/R 
1,3,6h+/- L-NIL 
(iNOS inhibitor) 
Serum ALT; 
histology; MPO 
 Increased IRI in iNOS(-/-); 
no iNOS mRNA or L-NIL 
effect in WT; genetic 
compensation effect  
Kawachi et 
al., 2000 
eNOS(-/-); 
iNOS(-/-) 
70% I 45 min/R 
5h 
Serum ALT; 
histology; MPO 
eNOS is activated in IRI 
and is protective 
No PMN infiltration and 
iNOS is not activated 
Devey et al. 
2009 
Hmox(-/-); 
Hmox(+/-) 
Left lobe I 40 or 
50 min/R 24 h 
Serum ALT; 
histology; WB; IH 
IRI activates Kupffer cells. 
HO-1 is protective 
 
IH: Immunohistochemistry; WB: Western blot; MPO: Myeloperoxidase; PCR: polymerase chain reaction; ELISA: Enzyme 
labelled immunosobert assay; EMSA: Electrophoretic mobility shift assay; AST: Aspartate transaminase; ALT:Alanine 
transaminase; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling (assay for cell death); GOT: glutamic 
oxaloacetic transaminase; I: ischemia; R: reperfusion; IR: ischemia reperfusion; IRI: ischemia reperfusion injury; TNF: 
tumour necrosis factor MMP: matrix metalloproteinase; Hmox: heme oxygenase gene; eNOS:endothelial nitric oxide 
synthase; iNOS: inducible nitric oxide synthase; HO-1: heme oxygenase (subtype 1); PMN: polymorphonuclear cell 
(neutrophil); WT: wild type animal 
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1.2.15. Downstream Pathways 
 
A wide range of downstream pathways have been studied in liver IRI. The majority of 
systems which are activated in ischaemia reperfusion are effective through these pathways. 
Some  of  the  key  mediators  activating  these  downstream  pathways  in  liver  IRI  are  TNFα,  
IFNβ,  IFNγ  and  CXCL10  (Figure  1.2.3.).  In  particular,  the  roles  of  the  transcription  factors  
nuclear  factor  kappa  beta  (NFκβ)  (Luedde  et  al.  2006),  the  survival  kinases  (JNK,  MAPK’s,  
PKC,  PI3K/Akt),  signal  transducer  and  activator  of  transcription  (STAT’s)  (Stephanou  et  al.  
2004), Poly ADP ribose polymerase (PARP), Peroxisome proliferator-activated receptor 
(PPAR) from pharmacological studies have been supported by knockout models of liver IRI. 
 
NFκβ  DNA  binding  increases  and  contributes  to  liver  IRI  (Wyllie  et  al.  2002;;  Kato  et  al.  
2000;;  Kuboki  et  al.  2007).  TNF  α  increases  NFκβ  activity  (Kato  et  al. 2000; Teoh et al. 
2004).  One  knockout  study,  in  contrast,  showed  a  fall  in  NFκβ  activity  following  liver  
reperfusion (Kuboki et al. 2008), although a longer period of ischaemia and reperfusion was 
used than other studies. Another group used a conditional  NFκβ  knockout  to  study  liver  IRI  
and  showed  NFκβ  activity  was  protective,  reducing  necrosis,  apoptosis,  JNK  expression  and  
TNF  α  expression  (Table  1.2.4).  Unlike  the  other  studies,  the  caudate  lobe  was  resected  in  
their protocol, which would activate inflammatory pathways following this surgical resection 
and cause additional circulatory and microcirculatory dysfunction. It is therefore unclear if 
the  role  of  NFκβ  in  IRI  is  protective,  injurous  or  depends  on  the  IR  protocol. 
A knockout model has provided evidence that interferon regulatory factor-1 (IRF-1) is 
released by IR, which in turn activates jnk-2, but not p38 MAPK, which contributes to liver 
IRI after reperfusion (Table 1.2.2) (Tsung et al. 2006). A jnk-2 knockout model of left lobe 
ischaemia using inhibitors of HO-1 and Kupffer cell depletion found a mechanism for IRI 
where IR activates jnk-2 which inhibits HO-1 mainly within Kupffer cells which contributes 
to IRI (Devey et al. 2009). 
 
Knockout models of PI3K and Protein kinase C (PKC) have been used in the heart, but not in 
the liver (Table 1.2.4) (Ban et al. 2008; Xuan et al. 2005). One group showed in a large 
animal pig model of orthotopic liver transplantation (OLT) using chelerythrine (a PKC 
inhibitor) and/or ischaemic preconditioning (IPC) of the donor liver before cold storage to 
show that PKC activity was not affected by IRI alone of OLT, although PKC was strongly 
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activated by IPC reducing the severity of IRI (Cursio et al. 2002; Ricciardi et al. 2001; 
Yanagida et al. 2004). 
 
Activation of the STAT family of transcription factors is mediated by extracellular signalling 
molecules such as cytokines which bind to membrane receptors which activate intracellular 
Janus kinases on the cytoplasmic face of the plasma membrane, which in turn activate a 
STAT protein which is then transported to the nucleus where they bind DNA to affect gene 
expression (Jak/STAT signalling pathway). STAT 6 activation does not appear to be involved 
in liver IRI based on results from knockout models (Kato et al. 2000; Shen et al. 2003). Kato 
et al. found in their model of IRI using STAT 4 knockouts that STAT 4 did not affect the 
extent of liver injury after 8 hours reperfusion (Kato et al. 2000). In contrast, Shen et al. 
showed STAT 4 expression was related to IRI after 6 hours of reperfusion, although it was 
specifically its expression within CD4+ T cells that mediated the liver injury (Table 1.2.4) 
(Shen et al. 2003). 
 
A knockout of PARP has been used to show that PARP activation contributes to early liver 
IRI (Table 1.2.4) and activates signalling pathways increasing expression of adhesion 
molecules on SECs (Khandoga et al. 2002). A liver IRI model using a PPAR knockout 
demonstrated background PPAR activity reduces the severity of liver reperfusion injury 
acting via signalling pathways that remain to be elucidated but appear not to involve NO or 
TNF  α,  both  of  which  act  independently  of  PPAR  in  this  model  (Okaya  et  al.  2004). 
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TABLE 1.2.4: Knockouts of downstream mediators and models of liver IRI 
 
Author/Yr Knockout 
model 
IR 
Protocol 
Outcome 
Measure 
Agent Adaptive 
Responses 
Injurous 
Responses 
Devey et al. 
2009 
jnk-2(-/-) Left lobe I 
40 min/R 
24h 
Serum ALT; 
histology; 
WB; IH 
ZnPP (HO-1 
inhibitor); 
liposomal 
clodronate 
(Kupffer cell 
depletion) 
HO-1 reduces 
IRI 
jnk-2 activation 
inhibits HO-1 in 
Kupffer cells 
contributing to IRI 
Shen et al., 
2003 
STAT4(-/-); 
STAT6(-/-); 
nu/nu 
70%I 90 
min/R 6h 
Serum ALT; 
histology; 
MPO; WB; 
PCR 
Adoptive 
transfer of 
CD4+ T cells  
 
HO-1 expressed 
at very low 
levels after 6h 
in this model, 
but protective  
CD4+T cell 
activation 
involving T cell 
STAT 4 activation, 
but not STAT 6 
increased IRI 
Kato et al., 
2002 
P50  NFκβ(-/-
) 
70% I 90 
min/R 1,8h 
Serum ALT; 
histology; 
WB;EMSA 
  No effect of p50 
subunit deletion 
Kato et al., 
2002 
STAT 4(-/-) 70% I 90 
min/R 30 
min, 
1,2,4,8h 
Serum ALT; 
histology; 
MPO; WB 
Anti IL12 Ab  IL12 associated 
with IRI. STAT 4 
not activated  
KO: transgenic knockout; WT: wild type (normal animals); IH: Immunohistochemistry; WB: Western blot; 
MPO: Myeloperoxidase assay; PCR: Polymerase chain reaction; EMSA: Electrophoretic mobility shift assay; 
ALT: Alanine transaminase; I: ischemia; R: reperfusion; IR: ischemia reperfusion; IRI: ischemia reperfusion 
injury; IFN: interferon; Ab: antibody; TNF: tumour necrosis factor; IL: interleukin; NF: nuclear factor;  STAT: 
Signal Transducer and Activator of Transcription; Jnk: a survival kinase;  
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1.2.16. Therapeutic Interventions 
A greater understanding of liver IRI from in vivo and in vitro pharmacological studies, 
knockout models and large animal studies have provided insights into possible therapeutic 
interventions at reducing IRI and improving clinical outcome. This has led to some initial 
clinical trials, using pharmacological preconditioning or surgical preconditioning (i.e. 
ischaemic preconditioning), the results of which are conflicting (Table 1.2.5).  
N-acetylcysteine (NAC) given to patients before liver transplantation showed no benefit, 
although the sample size was small, the recipients were at the healthier end of the spectrum 
and marginal donor livers were not used (Khan et al. 2005). One clinical trial in which 
patients inhaled NO preoperatively before liver transplantation showed improved liver 
function tests postoperatively (Lang et al. 2007).  Another clinical trial involved patients 
being given methylprednisolone intravenously preoperatively before liver transplantation 
showed reduced IRI (Aldrighetti et al. 2006). A preoperative dose of the protease inhibitor 
gabexate mesilate given to patients before major hepatic resection reduced the severity of IRI 
in one clinical trial (Kim et al. 2002). A multicentre prospective randomised control trial 
using a pancaspase inhibitor (IDN-6556) during cold storage/flush and intravenously after 
liver transplantation showed reduced liver cell apoptosis in recipients (Baskin-Bey et al. 
2007). 
Ischaemic preconditioning (IPC) where one or more short cycles of ischaemia and 
reperfusion preceding the main iscahemia reperfusion insult of the target organ, including the 
liver, has been shown to reduce IRI in most laboratory studies. In hepatic resection surgery, 
there is evidence that intermittent occlusion of the portal triad, although resulting in greater 
blood loss, is associated with lower rates of postoperative liver failure (9.6 vs. 0%) and lower 
mortality (4.6 vs. 0%) than continuous occlusion. Overall, however, the results have been 
conflicting, ranging from showing reduced IRI (Cescon et al. 2006; Clavien et al. 2003; Li et 
al. 2004), delayed graft function but reduced injury (Azoulay et al. 2005), no effect (Koneru 
et al. 2007) or even increased IRI (Koneru et al. 2007) with the IPC protocols used. 
A number of Cochrane reviews have been published assessing the benefits of protective 
strategies against liver IRI.  Several Cochrane reviews of IPC found not enough evidence to 
support or refute the use of IPC, but few trials were included and some were of high bias 
(Gurusamy et al. 2009). A Cochrane review assessing the effects of various pharmacological 
interventions concluded that trimetazidine, methylprednisolone and/or dextrose may protect 
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against ischaemia reperfusion injury in elective liver resections performed under vascular 
occlusions (Abu-Amara et al. 2009). There are several criticisms of this review. Only fifteen 
trials were used, they were high bias, different pharmacological interventions were pooled 
together for analysis and there were no statistically significant differences between groups in 
any of the clinically relevant outcomes of morbidity and mortality. 
 
1.2.17. Conclusions 
Liver IRI is a clinically relevant phenomenon in a wide range of settings including trauma 
surgery, hepatic resection and transplantation, affecting clinical outcome. Laboratory work 
using knockout models and large animal studies have provided insights into the mechanisms 
of liver IRI. Liver IRI occurs as a continuum beginning from the moment of reperfusion 
onwards for up to a week.  
Ischaemic preconditioning is a surgical method of reducing the severity of liver IRI. 
Understanding its molecular mechanisms and how this affects the pathways of liver IRI is a 
useful way of identifying putative protective pharmacological agents. In the context of large 
scale multicentre clinical trials that are more robust than previous trials offer the possibility 
of providing convincing evidence of techniques that can greatly reduce complications 
resulting from IRI in liver surgery as well as increasing the pool of usable allografts. 
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TABLE 1.2.5: Clinical Preconditioning Trials in Liver Surgery. 
Author/Year 
(Trial Type) 
Patient Group and 
Preconditioning Protocol  
Endpoints Results 
Azoulay et al./2005 
(RCT) 
OLT cadaveric transplant (n=45); 
Portal triad IPC (10I/10R) (n=46) 
 
Serum AST, ALT, INR, 
bilirubin (POD 1, 3) 
No effect of IPC 
Cescon et al. /2006 
(RCT) 
OLT (n=24); IPC (10I/15R) 
(n=23) 
iNOS, neutrophil 
infiltration, apoptosis, 
serum AST,ALT 
No clinical effect of IPC, 
but reduced apoptosis 
Khan et al./2005 
(RCT) 
OLT (n=9); NAC (i.v. portal 
flush) at donor operation (n=9) 
Peak AST, 1 hr post 
reperfusion biopsy 
No benefit of IPC 
Lang et al./2007 
(RCT) 
OLT (n=10); Inhaled NO (iNO) at 
80 ppm during recipient operation 
(n=10) 
 
Serum AST, ALT, 
APTT, hepatocyte 
apoptosis, length of 
hospital stay 
iNO improved rate of 
improvement of liver 
function and reduced length 
of hospital stay 
Aldrighetti et 
al./2006 (RCT) 
Liver resection (n=38); 
Preoperative  methylprednisolone 
(n=38) 
Serum AST, ALT, 
bilirubin, INR, IL6, 
TNFα  (POD  1,  2) 
Lower complication rate 
and serum markers in 
steroid group 
Kim et al./2002 
(RCT) 
Liver resection (n=25); Gabexate 
mesilate (GM) i.v. 24 hr preop 
until POD 3 (n=25) or GM 
beginning of surgery only (n=16) 
Serum  ALT,  TNFα,  
IL1β,  IL6 
Lower complication rate, 
including mortality and 
serum markers in GM group 
Baskin-Bey et 
al./2007 (Multicentre 
Phase II RCT) 
OLT(n=23); Pancaspase inhibitor 
IDN-6556 to organ storage/flush 
with (n=27) or without (n=23) 0.5 
mg/kg IDN-6556 to recipient 
Serum AST, ALT, 
apoptosis (TUNEL 
assay), caspase 3/7 
assay, histology 
Reduced apoptosis and 
serum markers when IDN-
6556 added, but no 
difference in complication 
rate 
Petrowsky, Clavien et 
al./2006 (RCT) 
Major liver resection 
(>bisegmentectomy) inflow 
occlusion > 30 min (n=50); IPC 
(10I/10R) (n=50) 
Serum AST, ALT, 
Liver ATP 
No clinical benefit of IPC, 
but improved  markers in 
younger and steatotic livers 
Li et al./2004 (RCT) Hepatic resection in HCC and 
cirrhosis under hepatic inflow 
occlusion (n=15); IPC (5I/5R) 
(n=14) 
Serum AST, ALT, 
bilirubin (POD 1, 3, 7), 
SEC apoptosis 
Improved serum markers, 
reduced apoptosis, length of 
stay and liver failure in the 
IPC group 
Koneru et al./2007 
(RCT) 
IPC (10I/10R) (n=50) Serum AST, ALT, 
bilirubin, INR (POD 1, 
2, 7), TNFα,  IL6,  IL10,  
Histology 
IPC associated with worse 
serum liver function tests 
but no significant clinical 
effect 
RCT=randomised controlled trial; OLT=orthotopic liver transplantation; IPC=ischaemic preconditioning; 
I=ischaemia time in minutes; R=reperfusion time in minutes; POD=postoperative day AST=aspartate 
transaminase; ALT=alanine transaminase; IL=interleukin; TNF=tumour necrosis factor; NAC=N-acetylcysteine
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1.3. LIVER ISCHAEMIC PRECONDITIONING 
 
1.3.1. INTRODUCTION 
Liver preconditioning is a pretreatment of the organ to reduce the severity of liver IRI. 
Ischaemic preconditioning (IPC) is a mechanical technique whereby a short period or several 
short periods of occlusion of the blood supply to an organ confers protection to the organ 
against IRI. This effect was first demonstrated in the canine heart by Murry et al (1986). This 
type of IPC is called direct IPC. Another form has been identified more recently where IPC 
of an organ or tissue different to the organ or tissue undergoing IRI reduces that injury, 
known as remote IPC (Kanoria et al. 2007). This chapter focuses on direct IPC to the liver. 
Current evidence supports the concept of two phases of protection of the liver against IRI by 
direct IPC. An early phase that protects within minutes of reperfusion lasting up to 3 hours, 
and a delayed phase of protection starting from 12 to 24 hours of reperfusion lasting several 
days (Bolli et al. 2000; Cohen et al. 2000; Yellon et al. 2000). Understanding the molecular 
signalling pathways for liver IPC offers the possibility of identifying agents that can 
pharmacologically precondition livers and eliminate the troublesome complications resulting 
from liver IRI in the clinical setting.  
 
1.3.2. INFLAMMATORY RESPONSE 
IPC decreases endothelial P-selectin expression in warm IRI of the rat liver (Sawaya et al. 
1999)  related  to  TNFα  downregulation  (Peralta  et  al.  2001). The resultant decrease in 
neutrophil adhesion, transmigration and activation protects the parenchyma. This decreases 
serum transaminase levels in hepatic IRI (Howell et al. 2000).  
Rat  pretreatment  with  low  dose  TNFα  (1-5 µg/kg body wt) before hepatic IR substantially 
reduces  liver  injury  and  TNFα  release,  while  high  dose  TNFα  exacerbates  injury  (Teoh  et  al.  
2003, 2004). This protective effect is associated with increased hepatocyte proliferation, 
increased IL-6 levels and increased STAT3 DNA binding (Teoh et al. 2006). It appears that 
IL-6  rather  than  TNFα  itself  seems  to  be  the  mediator  of  the  hepatoprotective  and  
proproliferative effects of IPC (Teoh et al. 2006). This is supported by using an IL-6 
knockout model of total hepatic ischaemia (THI), where IPC protected livers of wild type 
mice and was associated with increased STAT3 phosphorylation, whereas IPC has no effect 
in the knockout mice (Matsumoto et al. 2006). 
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1.3.3. MICROCIRCULATION 
A decrease in ROS production and neutrophil mediated injury by IPC leads to preservation of 
the microcirculatory architecture. This improvement in microcirculatory perfusion can be 
demonstrated by intravital microscopy showing improved sinusoidal perfusion (Vajdova et 
al. 2004; Zapletal et al. 1999). This microcirculatory improvement is further substantiated by 
laser Doppler studies of liver microcirculation (Koti et al. 2002). This improvement in 
microcirculation is associated with a fall in endothelin-1 (ET-1) (Kadono et al. 2006)and an 
increase in hepatic nitric oxide (NO) (Koti et al. 2002). 
 
1.3.4. ADENOSINE 
Peralta et al. showed adenosine acts as a trigger and mediator in liver IPC (Peralta et al. 
1998). This adenosine is produced by endothelial cells (Peralta et al. 1997, 1998). Nakayama 
et al. (1999) showed an A2 receptor agonist but not an A1 receptor agonist enhanced 
protection against THI. So, although liver cells express both A1 and A2a adenosine receptors, 
liver IPC acts through A2a receptors only (Dixon et al. 1996). 
In isolated hepatocytes, preconditioning is abolished by inhibiting heterotrimeric Gi protein or 
phospholipase C (PLC) with pertussus toxin and U73122, respectively (Carini et al. 2001). 
Direct stimulation of protein kinase C (PKC) with a DAG analogue prevents hypoxic liver 
cell injury, whereas PKC inhibition by chelerythrine prevents preconditioning protection in 
isolated hepatocytes or perfused livers (Carini et al. 2000; Ricciardi et al. 2001).This 
evidence supports that Gi proteins, PLC and PKC mediate the protective effects of liver 
ischaemic preconditioning by adenosine acting through A2a receptors.  
Stimulation of the adenosine A2a receptor is associated with a 2 to 3 fold increase in the 
activity of protein kinase B (PKB/Akt) (Carini et al. 2004). Experiments in isolated 
hepatocytes show activation of PKC leads to p38 MAPK phosphorylation (Carini et al. 
2001). The addition of activators of p38 MAPK protect while selective inhibition of p38 
MAPK during hepatocyte preconditioning abolishes the protection (Carini et al. 2001).  
 
1.3.5. NITRIC OXIDE (NO) 
NO plays an important role in mediating hepatic preconditioning. An increase in NO 
production is associated with the onset of liver tolerance to reperfusion injury, which is 
abolished by inhibiting NO release with L-NAME (Koti et al. 2002; Peralta et al. 1997, 2001; 
Arai et al. 2001). NO donors promote preconditioning even in the presence of NO synthase 
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inhibitors (Peralta et al. 2001). NO appears to act as a trigger in early IPC (Lochner et al. 
2002) and both a trigger and mediator in late IPC (Rakhit et al. 1999)  
The source of the NO is not established. The two main enzymes responsible for endogenous 
NO production are endothelial nitric oxide synthase (eNOS) and inducible nitric oxide 
synthase (iNOS). eNOS is constitutively present in liver endothelial cells and iNOS is 
expressed in virtually all cell types in response to stressful stimuli. There is evidence that 
eNOS is the source of NO in early IPC (Koti et al. 2005; Serracino-Inglott et al. 2005) and 
iNOS is the source of NO in late IPC (Shah et al. 2003). 
Isolated rat hepatocytes cultured under hypoxic conditions have improved cell survival when 
preconditioned by an NO donor (NOC-9), this protection being mediated by activation of 
soluble guanylate cyclase and cGMP dependent kinase (cGK), but not PKC. This 
cytoprotection is associated with increased p38 MAPK phosphoryation, which is abolished 
by inhibiting either guanylate cyclase or cGK (Carini et al. 2003). 
 
1.3.6. HAEM OXYGENASE-1 (HO-1) 
HO-1 is the inducible isoform of haem oxygenase and catalyses the formation of carbon 
monoxide (CO), biliverdin (which is converted to bilirubin by biliverdin reductase) and Fe2+ 
from haem degradation. Liver IPC is associated with increased HO-1 mRNA, followed by 
HO-1 protein expression and increased activity (Patel et al. 2004). In a rat model of warm 
liver IRI, the protective effects of liver IPC are associated with increased expression and 
activity of HO-1 (Coito et al. 2002; Lai et al. 2004; Massip-Salcedo et al. 2006). Cobalt 
protoporphyrrin (CoPP), an inducer of HO-1 reduces warm IRI, which is most dramatically 
evident after 24 hours reperfusion following the index ischaemia (Massip-Salcedo et al. 
2006). Hemin, another inducer of HO-1, reduces IRI in a rat ex vivo perfused liver model 
following storage of the liver for 16 hours at 4 oC in University of Wisconsin solution (Kato 
et al. 2003). The protection of IPC is abolished by inhibiting HO-1 with zinc protoporphyrrin 
(ZnPP) (Lai et al. 2004; Massip-Salcedo et al. 2006; Kato et al. 2003).  
HO-1 exerts its protective effects through its end products. CO reduced liver IRI in an ex 
vivo rat perfused liver model, where after 24 hours storage in cold preservation solution, ex 
vivo livers perfused with CO enriched blood showed less injury and this protective effect was 
even maintained in livers treated with ZnPP to inhibit HO-1 (Amesi et al. 2002). The CO 
mediated protection in this model was p38 MAPK dependent. In rat orthotopic liver 
transplantation (OLT) models, studies have shown that both CO being given to recipients or 
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CO enriched cold preservation solution reduced IRI (Ikeda et al. 2009; Kaizu et al. 2008). 
This protection relates microscopically to reduced sinusoidal endothelial cell (SEC) damage 
and reduced neutrophil extravasion (Ikeda et al. 2009). In contrast to the ex vivo model of 
Amersi et al., Kaizu et al found in their in vivo OLT model that p38 MAPK and JNK MAPK 
pathways were unaffected by CO (Kaizu et al. 2008). 
In one ex vivo rat perfused liver model, there was less liver IRI following 16 hours storage of 
livers in cold preservation solution when livers were perfused with bilirubin or biliverdin 
supplemented perfusion solution (Kato et al. 2003; Amersi et al. 2002; Ikeda et al. 2009; 
Kaizu et al. 2008; Fondevila et al. 2004). Similarly in a rat in vivo OLT model following 24 
hours storage of livers at 4 oC in University of Wisconsin solution, recipients and/or donors 
given biliverdin intravenously had less graft IRI (Fondevila et al. 2004). The other product of 
HO-1, Fe2+, in contrast, contributes to IRI. Fe2+ is thought to participate in the generation of 
free radicals through the Fenton reaction. Increased expression of the Fe2+ sequestering 
protein ferritin with IPC limits the severity of liver IRI (Berberat et al. 2003).  Bilirubin is a 
powerful antioxidant, its efficacy being enhanced under the hypoxic conditions of ischaemia 
and at micromolar concentrations scavenges ROS, protecting cells from peroxide radicals. Its 
antioxidant capacity may arise from a cycle in which biliverdin reductase undertakes 
NADPH-dependent reduction of biliverdin to bilirubin. The bilirubin is then oxidised by free 
radicals back to biliverdin and so this cycle continues (Baranano et al. Proc Natl Acad Sci 
USA 2002; Stocker et al. 1987). 
In summary, HO-1 is a protective mediator of liver IPC. This protection appears to be most 
evident in the late phase of IPC. This protection appears to be mediated through two of the 
the byproducts of HO-1: CO and biliverdin (Fig 1.3.1). 
 
1.3.7. HO-1 and NOS: IS THERE A CONNECTION? 
We have seen that NOS and HO-1 are important mediators of liver IPC. There is little data 
exploring the relationship between HO-1 and the NOS isoforms in liver IRI and the 
conclusions from the studies that have been done are conflicting. 
Acquaviva et al. (2008) used a warm THI rat model (30 minutes ischaemia and 3 hours 
reperfusion) to study the effects of coadministration of the antioxidants L-arginine and L-
rutin (Acquaviva et al. 2009). The antioxidants reduced liver IRI and increased eNOS and 
HO-1 protein expression and reduced iNOS expression. Since L-arginine is a substrate for 
NOS, it was concluded that eNOS expression increases HO-1 expression, which in turn 
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inhibits iNOS expression. In a rat OLT model, where donor rats were treated with adenovirus 
expressing HO-1 (or a control Ad-β  Gal  virus),  it  was  shown  that  that  HO-1 was induced in 
the Ad-HO-1 treatment groups with there being less liver IRI and reduced expression of 
iNOS in liver macrophages (Coito et al. 2002). 
In contrast, an in vivo mouse model of partial warm hepatic ischaemia (45 minutes ischaemia 
and 5 hours reperfusion) using wild type mice and transgenic overexpressors of eNOS with 
or without various HO-1 inducers and inhibitors showed that both eNOS and HO-1 activity 
reduced IRI, but they were independent of each other (Duranski et al. 2006). 
It is likely that there is a common activator for HO-1 and NOS induction in IPC. A good 
candidate for this is the oxygen sensitive transcription factor, hypoxia inducible factor, HIF-
1. HIF-1 is a transcription factor expressed ubiquitously in cells in response to hypoxia. HIF 
regulates the expression of nearly 200 genes that can affect the cellular adaptive responses to 
hypoxia and/or ischaemia. HIF-1 activates transcription of genes whose protein products 
either increase oxygen delivery to tissues (erythropoietin, EPO, via  erythropoiesis and 
vascular endothelial growth factor, VEGF, via angiogenesis) and provide metabolic 
adaptation under conditions of reduced oxygen availability by affecting a wide range of genes 
including those encoding glycolytic enzymes and glucose transporters (Hill et al. 2008; Loor 
et al. 2008; Semenza et al. 2000). In a study of cultured rat hepatocytes exposed to the effects 
of late phase hypoxic preconditioning, A2a receptor agonists and PKC and PI3K antagonists 
and assays of HIF-1 activation and hepatocyte death, it was shown that A2a receptor 
activation, PI3K and PKC activation increase HIF-1 activation which reduces hepatocyte 
death (Alchera et al. 2008). 
HIF is also thought to affect cell survival in IRI by regulating genes for HO-1, iNOS and 
cyclooxygenase-2 (COX-2), all associated with increased resistance to IRI. Double 
knockouts of HIF usually die in utero. Heterozygote knockouts for a single allele are viable 
(hif+/-), but have not been studied in liver IRI. Hill et al. used hif1a+/- and hif2a+/- mice in a 
model of unilateral renal ischaemia reperfusion injury (30 minutes ischaemia/72 hours 
reperfusion) to show that wild type mice had less renal reperfusion injury. In this model, HIF-
1 activation occurs during renal IRI and reduces the extent of renal IRI. 
 
1.3.8. CONCLUSIONS 
IPC has been shown to be protective in a number of animal models and some small clinical 
trials. Adenosine, NO and HO-1 are important mediators of liver IPC. It appears that 
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adenosine acts as a trigger and mediator in the early phase of IPC. NO is a key mediator in all 
phases of liver IPC. It is less clear what the source of the NO is. Current evidence supports 
that in early IPC, NO is released by eNOS and in late IPC it is released by iNOS. HO-1 
appears to be protective in the late phase of IPC acting through its products CO and biliverdin 
with elimination of the toxic product Fe2+. The interrelationship between the upstream 
mediators is poorly understood.  
 
There are few transgenic knockout or overexpressor models to provide robust mechanistic 
information about IPC and substantiate findings of other studies. The role of nitric oxide 
synthase in the protective effects of liver IPC is not well understood and its relationship to 
HO-1 expression and the in vivo timecourse of expression of these enzymes need to be 
clarified. This will provide important information that can be used in the consideration of 
identification and designs for pharmacological studies aimed at reducing liver IRI clinically. 
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Figure 1.3.1: Summary of current 
understanding of molecular 
mechanisms of Liver Ischaemic 
Preconditioning. sGC=soluble guanylate 
cyclase; cGK=cGMP dependent kinase; 
??=inconclusive evidence for this 
pathway. Some key triggers and 
mediators are highlighted in green.  
Following ischaemic preconditioning, 
adenosine released activates A2a 
receptors which acts through the 
PI3/Akt, PKC and PLC/DAG pathways to 
reduce the severity of cellular IRI. The 
downstream mediators for this 
protection are the survival kinases, 
specifically  p38  and  JNK  MAPK’s.  Nitric  
oxide (NO) released early from eNOS 
and late from iNOS is stimulated by 
adenosine and HIF-1. Acting through 
sGC (soluble guanylate cyclise), cGMP, 
cGK (cytosolic guanylate kinase) and 
p38/JNK MAPK in sequence, cell injury is 
reduced. HO-1 is activated possibly by 
NO or HIF-1, which protects through its 
products CO and biliverdin and by 
inhibiting excessive activation of iNOS, 
as high levels of NO can exacerbate cell 
injury. The protection of CO may be 
mediated by p38/JNK MAPK’s. 
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CHAPTER 2 
 
Methods 
 
An in vivo mouse model  of partial warm hepatic ischaemia reperfusion (IR) was 
used. Normal and transgenic double knockout for eNOS (eNOS-/-) mice were used. A 
partial warm liver IR model was used where ischaemia was applied to cephalic lobes 
only followed by reperfusion. Ischemic preconditioning (IPC) consisted of ischaemia 
applied directly to the cephalic lobes followed by reperfusion then IR to the cephalic 
lobes. The endpoints measured were surface Laser Doppler flow to assess liver 
microcirculation during the experiment and at the end of the experiment serum ALT, 
liver histological injury scores, Western blotting for eNOS, iNOS, phosphorylated 
eNOS (p-eNOS), HO-1 protein and RT-PCR for HO-1 mRNA. 
 
2.1 Animals 
All procedures and animal care were in accordance with the U. K. Home Office 
licensing regulations. C57 BL6 animals with targeted deletion of the enos gene by 
neomycin resistance gene insertion were supplied by the Welcome Institute 
(Biological Research, UCL) and bred by homozygote to homozygote mating in 
accordance with local regulations. Wild-type strain specific controls were obtained 
from commercial sources (Harlan UK Ltd, Bicester, Oxford). All animals were male, 
8 to 12 weeks old. 
 
The eNOS-/- mice were viable at 8 to 12 weeks, appeared as healthy as wild type 
mice, there were no anatomical differences intraabdominally on laparotomy and were 
as stable as wild type mice under general anaesthesia. 
 
2.2. Operative Procedure 
 
Animals had free access to food and water. All procedures were in accordance with 
the U. K. Home Office regulations and conformed with the NIH guidelines for the 
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care and use of laboratory animals. Animals were not fasted before the procedure, as 
this is not required for mice as they do not cannot vomit. 
 
Animals were anaesthetised with 2% isoflurane inhaled within an induction chamber. 
Anaesthesia was maintained by 1-5-2% isoflurane via a concentric oronasal mask 
connected to an anaesthetic circuit. Respiratory rate and depth were monitored 
visually and core temperature was monitored by a rectal probe and maintained using a 
heating pad.  The abdomen of animals was shaved and was cleaned with 2% 
chlorhexidine solution. The abdomen was draped with a single sterile drape with 
rectangular cut out to expose the operative site. Normal saline was administered 
subcutaneously to animals at the end of ischaemia 10 ml/kg to cover the duration of 
the experiments. For recovery experiments, analgesia in the form of buprenorphine 
0.01 mg/kg subcutaneously was administered at the end of the experiment before 
recovering the animals. 
 
A midline laparotomy was performed. The cephalic end of the wound was retracted 
avoiding contact with the viscera to obtain good exposure of the liver. The falciform 
ligament was cut in all groups. Viscera were handled gently with the ends of cotton 
buds wetted in sterile normal saline only. The small bowel was extruded and wrapped 
in swabs soaked in normal saline to optimise exposure of the liver. When undertaking 
ischaemia and reperfusion with or without preceding ischaemic preconditioning, a 
partial (70 %) hepatic ischaemia model was used where portal vessels to the lateral 
and median lobes were occluded (the so called cephalic lobes). This prevents 
mesenteric congestion by allowing portal vein decompression through the right and 
caudate lobes, bypassing the cephalic lobes. 
 
The ligament between the caudate and lateral lobes was cut up to the portal vessels 
under a dissecting microscope (Zeiss). The plane under the portal vessels was 
developed by gentle blunt dissection using curved microsurgical forceps. Haemostasis 
was ensured and bleeding was minimal, soaking the end of one wetted cotton bud at 
most. An atraumatic clip was placed across the portal triad to the cephalic lobes under 
direct vision. Correct placement was confirmed by a colour change of the cephalic 
lobes to an ischaemc dark ruddy purple, the right and caudate lobes turned a suffused 
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red colour and the small bowel did not change colour. On removing the clip at the end 
of the ischaemia time, all lobes became a suffused purple/red colour before returning 
to a normal pink colour within 5 minutes. During the index ischaemia period the 
laparotomy was closed with clips to ensure good core body temperature control. The 
clips were removed at the end of the ischaemia time. 
 
For nonrecovery experiments, the laparotomy was reclosed with clips once 
reperfusion had been established until the end of the designated reperfusion period, 
when blood samples were obtained by cardiac puncture through an anterolateral 
thoracotomy. The animal was terminated by cervical dislocation. Tissue samples were 
stored in liquid nitrogen for protein and mRNA analysis and at 4oC in 10% formalin 
for histology. For recovery experiments, the laparotomy was closed in two layers, 
with mass closure with 4.0 Vicryl as a continuous layer and 4.0 Vicryl interrupted, 
buried layer to skin. 0.05 mL of buprenorphine was given subcutaneously for 
postoperative analgesia and the animals were terminated 24 hours later as with the 
nonrecovery groups. 
 
2.3. Histopathology 
After euthanasia, representative pieces of ischemic, I/R, or bypass lobes are quickly 
removed and fixed in ice-cold 10% phosphate-buffered formalin for 24 h at 4°C. The 
tissue is then partially dehydrated with ethanol and embedded in plastic mounting 
medium using standard histological methods. Five-micrometer sections are cut and 
stained with hematoxylin and eosin. Several sections from each animal and given an 
overall score by an experienced liver pathologist blinded to the experimental group 
and conditions. The scoring system used was the Suzuki classification for liver 
ischaemia reperfusion injury. This is summarised in Table 2.1 below. The maximum 
score is 12, minimum score is 0. The mean score was taken for each group +/- sem. 
Numerical Assessment Sinusoidal Congestion Vacuolisation/Ballooning Necrosis 
0 None None None 
1 Minimal Minimal Single Cell 
2 Mild Mile <30% 
3 Moderate Moderate 30-60% 
4 Severe Severe >60% 
 
Table 2.1: Suzuki classification of histological injury following ischaemia reperfusion 
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2.4. Measurement of Hepatic Microcirculation (HM) 
 
HM was measured by a surface LDF (DRT4, Moor Instruments Limited, Axminster, 
UK) in flux units. The Doppler signal varies linearly with the product of the total 
number of moving red blood cells in the measured volume of a few cubic mm 
multiplied by the mean velocity of these red blood cells. The numeric product is 
termed perfusion units or blood cell flux units. The LDF probe was placed on a fixed 
site on the surface of the left lateral lobe of the liver and was held in place by a probe 
holder. LDF dam were collected continuously at sampling rate of 2 Hz. LDF 
measurements at the relevant time points were collected as a mean of 1-minute data. 
 
2.5. Measurement of Hepatocellular Injury 
 
A sample 0.2-0.5 mL of blood was collected from each animal by cardiac puncture 
via an anterolateral thoracotomy followed immediately by euthanasia by cervical 
dislocation. Serum alanine aminotransferase (ALT) was measured on a Hitachi 747 
auto-analyzer using commercially available enzymatic kit tests. The tests were 
determined using reagents supplied by Boehringer Mannheim Ltd (Lewes, Sussex, 
UK). 
 
2.6. Western Blot 
Western blots were performed on liver samples from the animal groups to assess 
protein expression of eNOS, phosphorylated eNOS (p-eNOS), iNOS and HO-1. 
 
Preparation of Protein Extracts 
 
Samples of liver tissue (100–200 mg) were crushed in liquid nitrogen using a 
sterilised pestle and mortar. The crushed tissue was immediately scooped into fresh 
sterilised tubes and weighed. The cell pellet was suspended in 300 microlitres of Ripa 
Buffer with protease inhibitor (Thermo Scientific EDTA-free protease inhibitor 
cocktail 10 microlitres per I mL cell extract) and vortexed for 15 minutes with breaks 
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in between. The samples were centrifuged at maximum speed for 5 minutes at 4 oC. 
Aliquots of 50 microlitres of the supernatant were taken. 
 
Lowry Technique of Protein Quantification 
 
Standard solutions of albumin solution were prepared with Phosphate Buffered Saline 
(PBS) according to manufacturers instructions (xxx) and 10x and 100x dilutions of 
samples were prepared. Modified Lowry Protein assay Reagent (1 mL) was pipetted 
into a second set of labelled tubes followed by 200 microlitres of diluted standards 
and sample into the individually labelled tubes. The tubes were vortexed and left to 
incubate for 10 minutes at room temperature. A preprepared dilution of 1x Folin-
Ciocalteu reagent (100 microlitres) was then added to all the standard tubes and 
samples, the tubes were vortexed and incubated for 30 minutes at room temperature. 
The standards were run in the spectrophotometer (read at 750 nm) programmed to 
calibrate absorbance  against a standard Lowry protein concentration graph. The 
diluted samples were then run in the spectrophotometer. The sample concentration 
read outs were used to calculate the original sample protein concentrations in the 
sample aliquots. This was used to standardise protein concentration across wells 
during Western Blotting.  
 
SDS gel electrophoresis and Western blotting 
 
In order to load enough total proteins to each well, protein samples were diluted to 10 
micrograms/microlitre made up to a volume of 30 microlitres with Ripa Buffer in new 
sterilised tubes. Laemlli Sample buffer 2x (30 microlitres) was pipetted into the new 
tubes. The samples were vortexed, heated in a water bath set at 95oC. This cycle of 
vortexing and heating was repeated another two times. The samples were then 
centrifuged at 7400 rev/minute for a few seconds.  
 
The samples were then loaded onto precast NuPAGE 4–12% gradient gels. 
Solubilized proteins were subjected to NuPAGE system (Invitrogen Life 
Technologies, Paisley,UK) on the precast gels using NuPAGE MOPS running buffer 
and electrophoretically transferred onto PVDF membranes using NuPAGE Western 
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blot Transfer  buffer. After blotting the membranes, the transfer of proteins was 
checked using Ponceau S stain. All subsequent steps were performed under gentle 
agitation. The membranes were then blocked using PBS containing 5% Marvel, 1% 
and 0.05% Tween 20 for 30 minutes. Next, the membranes were incubated with 
appropriate primary antibody (polyclonal rabbit anti-eNOS, anti-phosphorylated 
eNOS,  anti-iNOS, anti-HO-1 and 1:200 dilution, (Santa Cruz Biotechnology) 
overnight at 4°C. Next the membranes were washed three times for 5 min and one 
time for 15 min with PBS Tween 0.05%. Then the membranes were incubated for 2 h 
at room temperature with donkey anti- rabbit IgG HRP secondary antibody (1:200 
dilution). The washing steps were then repeated, and to detect any proteins that bound 
the antibody, the membranes were incubated with West Dura reagents (Perbio, 
Cheshire,UK)  for  5  min  according  to  the  manufacturer’s  instructions.   
 
The membrane was exposed to a digital camera as part of an electronic imaging 
system to visualize the proteins bound to the antibody. Blots were quantified by 
densitometric analysis of each protein band compared with a background reading 
from each membrane using an image analysis system (Molecular Analyst/PC, 
Windows Software for Bio-Rad’s  (Hercules,  CA)  Image  Analysis  Systems  Version  
1.5, and the data are expressed in relative optical density (OD) units. 
 
2.7. Reverse Transcription Polymerase Chain Reaction (RT-PCR):  
 
RT-PCR of liver samples was performed in all animals to assess expression of HO-1 
mRNA. 
 
Purification of Total RNA from Liver Tissue 
 
Weighed frozen tissue (20-30 mg) was immediately placed in liquid nitrogen and 
ground thoroughly with sterilised pestle and mortar. Tissue powder was decanted into 
RNase-free  2  mL  microcentrifuge  tube.  600  microlitres  of  Buffer  RLT    with  β-
Mercaptoethanol (made up to 1:100 in Buffer RLT) was added and vortexed for 15 
minutes. The lysate was centrifuged for 3 minutes at full speed and the supernatant 
was removed and transferred into a new microcentrifuge tube. Only the supernatant 
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was used in subsequent steps. One volume of 70 % ethanol in RNase-free H20 was 
added to the cleared lysate. Up to 700 microlitres of the sample supernatant was 
transferred to an RNeasy spin column placed in a 2 mL collection tube and 
centrifuged for 15 seconds at 10,000 rpm and the flow-through was discarded. 700 
micrlitres of Buffer RW1 was added to the RNeasy spin column and centrifuged for 
15 seconds at 10,000 rpm. This washed the spin column and the flow-through was 
discarded. 500 microlitres of Buffer RPE with 4 volumes of 96-100% ethanol was 
added to the RNeasy spin column. The spin column was centrifuged for 15 seconds at 
10,000 rpm and the flow-through was discarded. The last step was repeated 
centrifuging the spin column for 2 minutes rather than 15 seconds to dry the spin 
column and preventing ethanol is not carried over in the next steps. The RNeasy spin 
column was placed in a new 2 mL collection tube and centrifuged at full speed for 1 
minute. The RNeasy spin column is placed in a new 1.5 mL collection tube and 50 
microlitres of RNase-free H20 is added directly to the spin column membrane and 
centrifuged for 1 minute at 10,000 rpm to elute the RNA. The concentration of the 
RNA was measured by Gene Speck Machine. 
 
Reverse Transcription Reaction 
 
A volume of 10.5 microlitres of total RNA is mixed with 1 microlitre of 100 
micromol/litre of the REVERSE primer in a RNase free sterilised tube incubated for 5 
minutes at 95 oC to denature the linear RNA. The tube is spin centrifuged for a few 
seconds at maximum speed. While the tube is on ice, 2 microlitres of RT Buffer 
(10x), 5 microlitres of 4 dNTP, 0.5 microlitres of RNase Inhibitor and 0.5 microlitres 
RNase-free H20 were added to the tube. The mixture was vortexed and span down for 
1 minute at maximum speed. 1 microlitre of reverse transcriptase enzyme 9RT) is 
added to the mixture, vortexed and span down. The mixture is incubated for 2 hours at 
37oC to start the RT reaction of transformation from mRNA into cDNA. After the 
incubation is completed, the tube is transferred into a water bath at 70oC for 10 
minutes to deactivate the RT enzymes. 
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Polymerase Chain Reaction (PCR) 
 
All reactions used a RNase free tube. The PCR mix was made up over ice by adding 
25 microlitres of TopTaq Master Mix 25 microlitres, 1 microlitre of 1:4 of 100 
micomol/litre of FORWARD and of REVERSE primer, 5 microlitres of 10x 
CoralLoad, 16 microlitres of RNase-free H20 and 2 microlitres cDNA. This gives a 
total PCR mix volume of 50 microlitres. A control mix should be made up 
substituting the 2 microlites of cDNA with RNase-free H20. The PCR mix tube was 
placed on a PCR Express Machine on the following cycles: 95 oC for 15 minutes for 
1 cycle followed by 94 oC for 1 minute then 56 oC for 1 minute and then 72 oC for 1 
minute repeated for 30 cycles. The thermal cycling programme is ended with 1 cycle 
of 72 oC for 10 minutes. The samples are loaded into wells in a 2% E Gel for 15 
minutes and viewed using the image analyser system. 
 
 
Table 2.2. Haem Oxygenase -1 (HO-1) Primers 
 
Forward Primer 5’-CACAGGGTGACAGAAGAGGCTAA-3’ 
Reverse Primer 5’-CTGGTCTTTGTGTTCCTCTGTCAG-3’ 
 
Statistical Analysis 
Data was entered into and analysed using SPSS 14.0. The values were expressed as 
means+/- standard error. Means were compared using one-way ANOVA  with 
posthoc Tukey analysis unless otherwise stated. P<0.05 was considered significant. 
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CHAPTER 3 
 
OVERVIEW OF EXPERIMENTS 
 
3.1. Partial Liver IR Model 
 
During hepatic resection and liver transplantation surgery there are distinct periods of 
warm hepatic ischaemia followed by reperfusion. When the period of ischaemia is 
prolonged in this clinical setting, reperfusion results in liver IR injury, which is 
associated with organ dysfunction, acute liver failure, multiorgan failure and death.  
Developing in vivo models that reflect human IR injury help us better understand the 
mechanisms of liver injury and will help us to develop interventions that protect 
against IR injury clinically. 
 
In models of warm hepatic ischaemia and reperfusion, hepatic ischaemia induced by 
occluding the portal vessels either with a tie or clamp most closely approximates the 
intraoperative situation that occurs during liver surgery.  
 
Partial hepatic ischaemia prevents splanchnic congestion allowing decompression of 
the portal venous flow through perfused liver lobes. Total hepatic ischaemia causes 
portal venous congestion resulting in gut oedema causing increased gut wall 
permeability leading to translocation of bacteria forming the normal microflora into 
the portal system leading to portal endotoaxeamia and a systemic inflammatory 
response and sepsis. Thus partial lobar hepatic ischaemia in theory more specifically 
probes the pathophysiological mechanisms of liver IR injury without interactions 
from effects on the gut influencing results, in addition to replicating conditions in 
partial liver resection surgery. Small animals tolerate partial hepatic ischaemia better 
and the liver IR injury is less severe than for the equivalent global hepatic ischaemia 
times as discussed in Chapter 1.2.2. In mice, partial (70%) ischaemia of 45 to 60 
minutes with reperfusion from 1 hours onwards consistently show evidence of IR 
injury with minimal animal mortality (Hines et al. 2002, Kawachi et al. 2000, Lee et 
al. 2001, Tsung et al. 2006, Wyllie et al. 2002). Therefore in the present study, the use 
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of a mouse warm partial (70%) hepatic ischaemia reperfusion injury model with 45 
minutes ischaemia and 2 hours reperfusion was felt to be justified to study liver IRI. 
 
3.2. Endpoints of Liver Injury 
 
The three endpoints of serum ALT, surface Laser Doppler flowmetry assessment of 
liver microcirculatory dysfunction and histological injury scoring were used as 
endpoints of liver IR injury. A prolonged period of liver ischaemia followed by 
reperfusion results in liver IR injury. The resulting hepatocellular injury releases liver 
transaminases into the circulation which are detected within 1 hour of reperfusion 
(Wyllie et al. 2002; Hines et al. 2001). Therefore, with liver IR injury serum liver 
transaminases, such as ALT, GGT and AST are raised. Liver serum transaminases 
reach peak levels in IR between 6 and 12 hours of reperfusion (Shimamura et al. 
2005; Kuboki et al. 2008). Longer periods of liver ischaemia result in greater IR 
injury and higher levels of serum transaminases for a given period of reperfusion 
(Yoshizumi et al. 1998; Yadav et al. 1999). 
Liver IR injury can be demonstrated histologically initially by progressive sinusoidal 
congestion, hepatocyte vacuolisation and ballooning occurring within an hour of 
reperfusion, followed by progressive hepatocellular necrosis and apoptosis and 
neutrophil infiltration from 6 hours reperfusion onwards (Kato et al. 2002; Hines et al. 
2002; Kawachi et al. 2000).  Longer periods of ischaemia result in more severe 
histological liver injury with enhanced hepatocellular necrosis evident as more 
extensive pyknotic nuclei, cytoplasmic blanching and loss distinct hepatocellular 
borders (Hines, Hoffman et al. 2003). These are best observed under high power 
microscope of stained sections of liver and with electron scanning microscope. The 
most widely used histological scoring system in liver IR injury research is the Suzuki 
classification (Table 3.1), which is a validated scoring system for liver IR injury as 
discussed in Chapter 1.1.3. 
By definition liver IR injury involves a derangement of liver microcirculation. This 
has been demonstrated physiologically in a number of ways, including intravital 
fluorescence microscopy (IVFM) showing reduced red blood cell velocity and surface 
laser Doppler flowmetry signal (LDF). Surface LDF readings of the liver during IR 
have been validated as a technique of assessing the microcirculatory dysfunction that 
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occurs associated with liver IR injury. A previous study demonstrated in a rat model a 
linear correlation between red blood cell velocity as measured by IVFM and LDF 
signal across sham laparotomy, liver IR with hepatic artery ligation (HA) and 
nonarterialised liver transplantation (NOLT) groups. They showed greater 
microcirculatory dysfunction with the more severe IR injury that occurred in the 
NOLT group of animals compared to the HA group (Tawadrous et al. 2001). Longer 
periods of liver ischaemia causing more severe IR injury and microcirculatory 
dysfunction are associated with lower LDF signals (Kazuo et al. 1998).  Therefore 
LDF assessment of liver microcirculatory is a validated assessment technique and 
endpoint of liver IR injury.  
The more endpoints that are used, the more robust the validation is of a model.  In 
human liver transplantation increased warm and cold ischaemia time is associated 
with increased serum ALT, histological liver injury and impaired liver blood flow 
which are associated with reduced graft survival and increased mortality (Kelly DM et 
al. 2011; Friedman et al. 2012; Tzimas et al. 2004).As serum ALT, histological injury 
scoring and Laser Doppler flow assessment of liver microcirculation are validated 
endpoints for demonstrating liver IR injury, in the current study, we used all three 
endpoints to validate our model of liver IR injury. We found that anaesthesia for 3 
hours with sham laparotomy did not result in liver IR injury, as there was no rise in 
serum ALT, no histological injury, or any derangement in liver microcirculation.  
 
3.3. Selection of IPC Protocol to Study Protection versus Liver IR Injury 
 
Ischaemic preconditioning (IPC) is a therapeutic strategy to reduce liver IR injury. 
The protective effect is dependent on the timing of ischaemia and reperfusion in IPC 
that precedes index IR that results in IR injury. The mechanism of IPC remains 
controversial and hence no individual measurement can determine the adequacy of the 
preconditioning stimulus. As a result it is the effect on liver IR that is being measured 
via the validated endpoints of IR that were discussed above. Systematic studies of 
different IPC protocols on murine models of partial hepatic IR showed that IPC of 10 
minutes ischaemia (but not 5 or 15 minutes) and 10 or 15 minutes reperfusion 
protected against 75 and 90 minutes ischaemia  followed by reperfusion (Yadav et al. 
1999; Teoh et al. 2002; Vajdova, Heinrich and Clavien 2004). These previous 
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systematic studies showed somewhat variable results between them for timeframes of 
ischaemia and reperfusion of IPC that were protective against IR injury with small 
differences leading to a loss of protection by IPC. Also, in our mouse partial (70%) 
warm hepatic IR model of liver IR injury, the ischaemia period of 45 minutes we used 
is shorter than the above systematic studies of IPC protocols. It was therefore 
appropriate to establish an IPC protocol that reduces the liver IR injury in our model 
with a preliminary systematic study of different IPC protocols and their effects on 
liver IR injury.   
 
3.4. EXPERIMENTAL GROUPS 
 
Normal (i.e. wild type) C57Bl6 mice were randomly allocated to three groups, 5 
animals per group: 
1. Sham laparotomy. 
2. IR only: index ischaemia reperfusion (45 min ischaemia/120 min reperfusion). 
3. Ischaemic preconditioning (IPC) followed immediately by index ischaemia 
reperfusion. 
 
In the Results Chapter 4, preliminary experiments done to establish best protective 
protocol of IPC. The IPC protocols investigated in the current study consisted of 
ischaemia of 3 minutes and reperfusion of 10 minutes (IPC 3/10), IPC 5/10, IPC 
10/10 and IPC 10/15, which were felt to be reasonable IPC protocols based on 
previous systematic IPC studies discussed above. 
In Chapter 4, we found that only IPC 5/10 was protective against liver IR injury in our 
model of partial liver IR. Therefore, in subsequent chapters we used this IPC protocol 
to study the effects of IPC on  liver IR injury. 
Nitric oxide is an important mediator of liver IPC and protection against liver IR 
injury, but the role of endothelial nitric oxide synthase (eNOS) is unclear. The main 
advantage of using mice for IR research is that many transgenic strains are available. 
The use of transgenic strains offers a robust method of studying the functions of 
various genes and their products, thereby providing insights into the molecular 
mechanisms underlying liver IR injury and IPC. Therefore the role of eNOS in IR 
injury and IPC was studied using eNOS transgenic knockout (eNOS-/-) mice, which 
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do not express eNOS. The same partial hepatic IR model was used as for wild type 
mice and the effect of IPC of 5 minutes ischaemia and 10 minutes reperfusion was 
evaluated. Three groups of eNOS-/- mice were studied: 
1. Sham laparotomy. 
2. IR only: index ischaemia reperfusion (45 min ischaemia/120 min reperfusion). 
3. Ischaemic preconditioning (IPC) followed immediately by index ischaemia 
reperfusion. 
 
In Results Chapter 5 the effects of sham laparotomy and IR only in eNOS-/- animals 
was compared to wild type (WT) animals on the three endpoints of serum ALT, liver 
histological injury and liver microcirculation (as measured by LDF). In Results 
Chapter 6 the effects of IPC on liver IR injury on the three endpoints was compared 
between eNOS-/- and WT animals. In Results Chapter 7 the effects of sham 
laparotomy, IR only and of IPC on IR injury on liver protein expression (eNOS, 
phosphorylated eNOS, HO-1) and HO-1 mRNA was compared in wild type animals 
and eNOS -/- animals. Protein expression for eNOS and phosphorylated eNOS was 
also studied, but only in wild type animals, as eNOS-/- mice do not express eNOS. 
 
In Chapter 7 we found that HO-1 protein was not detected in ay of the experimental 
groups, but HO-1 mRNA was detected in all experimental groups. Therefore, in 
Results Chapter 8 we developed a model of late phase IR with recovery from 
anaesthesia  (“recovery  experiments”)  to  assess  if  HO-1 protein expression followed a 
delayed timecourse. This consisted of 3 groups of wild type mice: 
1. Sham laparotomy, recovery, euthanased 24hr later. 
2. IR only: index ischaemia reperfusion (45 min ischaemia/ 24 hr reperfusion) 
only, recovery, euthanased 24 hr later. 
3. IPC (5 minutes ischaemia and 10 minutes reperfusion) followed immediately 
by index ischaemia reperfusion (45 min ischaemia/ 24 hr reperfusion), 
recovery, euthanased 24 hr later.     
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 1.Sham                                                                                                                                             BL  5 minutes                    60 minutes                       120 minutes    cardiac  puncture  for  serum ALT                                                                           Animal termination and Liver for histology    2. IR                           BL                      5 minutes                    60 minutes      120 minutes                                                                                  cardiac  puncture  for  serum ALT                                                                                                     Animal termination and Liver for histology  3. IPC+IR                                             BL                                                              5 minutes                   60 minutes     120 minutes               cardiac  puncture  for  serum ALT                                                                                                                                                         Animal termination and Liver for histology 
 
Figure 3.1. Experimental groups for nonrecovery experiments.  
Thin arrows as labelled; BL. Baseline; HI. Ischaemia period during IPC; HR. Reperfusion 
period during IPC. For the longer term recovery experiments, ischaemic interventions were 
identical to those shown in 3. IPC + IR except that the recovery period was extended from 2h 
to 24h 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liver Perfusion 3hours 
Liver ischaemia 45 minutes Liver perfusion 2 hours 
Liver ischaemia 45 minutes Liver perfusion 2 hours 5 minutes 10 minutes 
HI HR 
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CHAPTER 4:  
 
SYSTEMATIC STUDY OF IPC PROTOCOLS IN A MOUSE 
MODEL OF LIVER IRI  
 
4.1. INTRODUCTION 
 
Liver ischaemia reperfusion injury (IRI) occurs after prolonged ischaemia followed 
by reperfusion in the clinical setting, such as liver resection surgery and liver 
transplantation, as discussed in Chapter 1. This is corroborated by animal models of 
liver IR injury. As discussed in Chapter 1.2, the pathophysiology of liver IR injury is 
initiated by reactive oxygen species (ROS) during reperfusion which cause direct 
cellular injury and also activate a cascade of mediators leading to microvascular 
changes and activation of acute inflammatory pathways with leading to liver injury.  
 
Ischaemic preconditioning (IPC) is a potential therapeutic strategy to lessen liver IR 
injury. Liver IPC is a mechanical technique whereby a short period of occlusion of the 
blood supply to the liver confers protection against IR injury. This has been 
demonstrated in many large and small animal models of liver IR (Giovarnardi et al. 
2009, Yoshizumi et al.1998, Koti et al.2002, Funaki et al. 2002, Berasain 2006, Izuisii 
et al. 2006, Teoh et al. 2004, 2006). As discussed in Chapter 3.3., systematic studies 
of different IPC protocols on murine models of partial hepatic IR showed somewhat 
variable results between them for timeframes of ischaemia and reperfusion of IPC that 
were protective against IR injury with small differences leading to a loss of protection 
by IPC.  
 
In this chapter, the first aim was to confirm that early phase liver IR injury occurred  
in a mouse partial (70%) warm hepatic IR model with an IR protocol of 45 minutes 
partial (70%) ischaemia and 2 hours reperfusion (index IR).  The second aim was to 
different IPC protocols were protective against liver IR injury (Methods Chapter 2 
and Overview of Experiments Chapter 3), and therefore would be useful in studying 
the underlying protective mechanisms.  
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4.2. RESULTS 
 
During the operative procedure all animals remained stable and tolerated anaesthesia, 
IR and IPC. There was no intraoperative mortality in any of the animals. All the 
endpoints were achieved. 
 
Anaesthesia and Sham Laparotomy  
 
There was no evidence of liver injury in the animals with 3 hours of anaesthesia and 
sham laparotomy (control group), reflected by normal serum ALT and absence of 
histological liver injury.  (Figure 3.1 and Table 3.1).  
Liver microcirculation did decrease progressively from baseline to 120 minutes, but 
this was only a relatively small decrease to 90% of baseline (Figure 3.2).  
 
Effect of Liver IR  without IPC 
 
All the animals tolerated partial (70%) ischaemia of the cephalic lobes for 45 minutes 
followed by 2 hours reperfusion. IR injury was demonstrated by raised  serum ALT 
(1805+/-454 IU vs  sham 63+/- 33IU, p<0.05) and histological liver injury (score 
3.67+/-0.47 vs sham no injury with score zero all samples) in the form of hepatocyte 
necrosis, cellular ballooning and sinusoidal congestion at the end of 2 hours 
reperfusion (Figure 3.1, Figure 3.3 and Table 3.1). Liver microcirculation was 
impaired relative to baseline for the duration of reperfusion . The liver blood flow 
progressively decreased from 5 minutes after reperfusion to 2 hours of reperfusion 
down to 65% of baseline blood flow(Figure 3.2, P<0.01 1-way ANOVA).  
 
The effect of  different IPC protocols 
 
In the previous sections it was established that sham laparotomy with anaesthesia was 
not associated with liver IR injury and that the IR protocol of 45 minutes partial 
(70%)  hepatic ischaemia and 2 hours reperfusion (index IR) did result in liver IR 
injury. Following this, different IPC protocols were tested consisting of a single cycle 
of a short period of ischaemia followed by a short period of reperfusion, as described 
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in the Methods section (3.2), to assess if any of these IPC protocols had a protective 
effect in reducing the IR injury resulting from the index IR. The endpoints used to 
assess the effects of different IPC protocols were serum ALT and LDF measurements 
of liver microcirculation as described in section 3.2. 
 
There was no significant difference in the serum ALT compared to index IR with an 
IPC protocol of IPC 3/10 (IR serum ALT 1805 IU+/- 454 versus IPC 3/10 serum ALT 
2050 IU+/-378 P=0.38) and IPC 10/15 (IR serum ALT 1805 IU+/- 454 vs IPC 10/15 
serum ALT 1580 IU+/-393 P=0.26) (Figure 3.1). There was no improvement in the 
microcirculatory dysfunction measured by LDF resulting from index IR alone when 
IPC 3/10 or IPC 10/15 preceded IR (P=0.32 and P=0.21, respectively Figure 3.2).  
 
Animals undergoing IPC 10/10 preceding index IR had significantly higher serum 
ALT than animals in the IR only group  (serum ALT 2910 IU+/- 219 versus 1805 
IU+/-454 respectively, P<0.05, Figure 3.1). The liver microcirculatory dysfunction 
found in the IR only group was not improved by IPC 10/10 and actually appeared on 
visual inspection to be more severe in the IPC 10/10 group than the IR only group, but 
this did not reach statistical significance (P=0.10, Figure 3.2).  
 
IPC of 5 minutes ischaemia and 10 minutes reperfusion (IPC 5/10) was the only IPC 
protocol used that reduced the severity of IR injury. This was reflected by a reduction 
in serum ALT compared to the IR only group of animals (560+/-218 IU versus 
1805+/-454 IU respectively, P<0.05, Figure 3.1). The impairment in liver 
microcirculation observed throughout the 2 hour reperfusion period in the IR only 
group was also abrogated with IPC 5/10 (P<0.05 ANOVA, Figure 3.2). As this was 
the only IPC protocol that reduced IR injury based on the two endpoints, liver 
histopathology was also examined at the end of index IR, as described in the Methods 
section 3.2, as a third endpoint to validate the protective effects of IPC 5/10 more 
robustly. There was reduced liver histological injury with less hepatocyte necrosis and 
ballooning at the end of index IR in the IPC 5/10 group of animals compared to the IR 
only group (IPC 5/10 group histological score 1.67+/-0.47 versus IR only group score 
3.67+/-0.47, P<0.05, Figure 3.3).  
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4.3. DISCUSSION 
 
In this study a mouse model of partial (70%) hepatic IR was used to investigate liver 
IR injury and the effects of different IPC protocols preceding index IR on IR injury. 
The model was found to be robust and reliable. In this model sham laparotomy did not 
result in IR injury. Index IR consisting of partial (70%) ischaemia of cephalic lobes 
and 2 hours reperfusion resulted in liver IR injury. An IPC protocol consisting of 5 
minutes partial (70%) ischaemia to cephalic lobes and 10 minutes reperfusion (IPC 
5/10) followed immediately by index IR reduced the hepatocellular injury, 
histological changes and microcirculatory dysfunction of IR injury. IPC 3/10, IPC 
10/10 and IPC 10/15 did not reduce IR injury. So, in this model, of the IPC protocols 
studied, only IPC 5/10 was protective against liver IR injury. 
 
The animals tolerated partial (70%) ischaemia of the cephalic lobes for 45 minutes 
followed by 2 hours reperfusion. There was liver IR injury in this group. Liver IR 
injury was demonstrated in this mouse model of warm IR as elevated transaminases, 
impaired parenchymal perfusion and increased histological injury score. The 
demonstration of IR injury in this mouse model of liver IR and no liver injury with 
sham laparotomy is as noted in previous studies (Hines et al. 2001, 2002). 
 
There was liver IR injury in all the IPC groups. Liver IR injury was demonstrated 
with all the IPC protocols in this mouse model by elevated transaminases and 
impaired parenchymal perfusion. In the IPC 3/10 and IPC 10/15 groups there was no 
statistically significant difference or obvious visual difference from the graphs of 
serum ALT and LDF in the severity of the IR injury compared to the IR group 
without IPC (Figure 3.1 and 3.2).  This is consistent with reports from previous 
studies using a similar IR model and IR protocol, although there are far fewer mouse 
models of IPC with IR than larger animal models and many of these mouse models 
use longer ischaemia times for index IR than our model (Ishii et al. Teoh et al. 2003).  
We did not use an index IR ischaemia time of longer than 45 minutes, as this was 
associated with high intraoperative animal mortality, which was felt not to add greatly 
to relevant data collection.  
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IPC 10/10 increased serum ALT compared to index IR without IPC and there was a 
visual trend in the graph of LDF towards increased microcirculatory dysfunction 
compared to index IR without IPC, although the LDF trend did not reach statistical 
significance. This would suggest that IPC of 10 minutes ischaemia followed by 10 
minutes reperfusion (IPC 10/10) before index IR of 45 minutes ischaemia and 2 hours 
reperfusion increases IR injury compared to index IR only in our mouse model. There 
is no data in the literature relating to these specific timings of IPC and IR for mouse 
partial (70%) hepatic IR models, however for equivalent rat models, studies have 
shown IPC 10/10 to reduce IR injury (Yoshizumi et al.1998; Koti et al.2002; Funaki 
et al. 2002; Berasain 2006; Izuisii et al. 2006 (BalB); Teoh et al. 2004, 2006). There 
may be a narrower time window of protection of IPC in mice than larger animals 
when index ischaemia times are 45 minutes or shorter in partial (70%) warm IR 
models, which would explain this difference between mice and larger animals. IPC 
10/10 causes more severe IR injury than IPC 10/15 in our model. This may be 
because in our mouse model 10 minutes of reperfusion is too short a period to activate 
any protective pathways following 10 minutes ischaemia before the injurious 45 
minutes index ischaemia is initiated. 
 
IPC of 5 minutes ischaemia followed by 10 minutes reperfusion (IPC 5/10) before 
index IR of 45 minutes ischaemia and 2 hours reperfusion reduced the severity of IR 
injury. This was demonstrated by three endpoints as a reduction in serum ALT, lower 
histological injury scores and improved liver microcirculation. One of the aims of this 
chapter was to establish an IPC protocol that was protective against liver IR injury. 
The groups of animals that underwent the other IPC protocols did not exhibit reduced 
liver IR injury based on serum ALT and LDF assessments of liver microcirculation. 
As there was no protection against IR injury with IPC 3/10, IPC 10/10 and IPC 10/15 
based on two endpoints, it was felt unnecessary to look at liver histology also as a 
third endpoint in these IPC groups.  Therefore, IPC 5/10 was the only IPC protocol of 
those used in the present study that reduced liver IR injury. This IPC protocol of 5 
minutes ischaemia is long enough to generate adequate substrates that initiate a 
protective pathway, but not so long as to be injurious, on reperfusion, while 10 
minutes reperfusion is long enough to set off a cascade of protective molecular 
signalling pathways. Previous studies using a mouse model of partial (70%) hepatic 
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IR with index ischaemia of 45 minutes or less have also found that IPC 5/10 is 
protective against liver IR injury (Sawaya et al. 1999; Howell JG et al. 2000). 
 
During index ischaemia livers were friable and the LDF probe occasionally caused 
visible trauma during liver ischaemia readings invalidating further LDF readings. As 
the experiments in this chapter were preliminary experiments for assessing liver IR 
injury and establishing a protective IPC protocol, having established LDF is severely 
impaired with IR with or without any of the IPC protocols, it was not felt justified to 
use a larger number of animals for each group without altering the conclusion of 
which, if any, IPC protocol was protective. Once this had been established, we 
intended to measure LDF during ischaemia, so in subsequent chapters LDF data 
during the ischaemia period will be included mainly for presentation reasons and to 
show similarly impaired microcirculation during ischaemia across the experimental 
groups. 
 
In conclusion, we described and validated a mouse model of liver IR that results in IR 
injury and established a direct IPC protocol that significantly reduces this liver IR 
injury. This model should prove useful in investigating liver IR injury and the 
protective mechanisms of direct IPC and opens up the possibility of using transgenic 
knockout animals to study the underlying mechanisms of liver IPC and IR injury. 
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Figure 4.1: Serum ALT in sham, IR and various IPC protocol groups. Values are 
means +/- s.d. of 5 animals in each group (*P<0.05 vs. sham and IPC 5/10; +P<0.05 
vs. sham, IR, IPC 3/10, IPC 5/10, IPC 10/15; &P<0.05 vs. sham). IR=ischaemia 
reperfusion; IPC+IR X/Y= ischaemic preconditioning (X minutes ischaemia, Y 
minutes reperfusion) preceding ischaemia reperfusion. 
 
*   + 
& 
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Figure 4.2: Liver microcirculation with sham, IR and different IPC protocols. Laser 
Doppler Flow (LDF) as percentage of preischaemia measurement at various 
timepoints during reperfusion after index ischaemia of 45 minutes for IR only and 
various IPC protocol groups and sham (no ischaemia). LDF was measured over the 
left lateral lobe of the liver for each group preischaemia (DBF 100% baseline value), 
following index ischaemia at 5 minutes, 60 minutes and 120 minutes reperfusion. 
Values are means+/-s.d. of 5 animals in each group. IR=ischaemia reperfusion; 
IPC+IR X/Y= ischaemic preconditioning (X minutes ischaemia and Y minutes 
reperfusion) preceding ischaemia reperfusion.  
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Figure 4.3: Liver histology for sham, liver IR only and IPC+IR groups. (A) Sections 
from the experimental groups (400X).  (B) Bar graph summarising histological 
scores. Values are mean +/- s.d. of 5 animals in each group (*P<0.05 vs. sham, 
#P<0.05 vs. IR). IR=ischaemia reperfusion only; IPC+IR= ischaemic preconditioning 
of 5 minutes ischaemia and 10 minutes reperfusion preceding ischaemia reperfusion. 
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CHAPTER 5 
 
COMPARISON OF ISCHAEMIA REPERFUSION INJURY (IRI) 
in eNOS-/- and WILD TYPE ANIMALS 
 
5.1. INTRODUCTION 
 
Our current understanding of the mechanisms of liver IR injury was discussed in 
detail in Chapter 1.2. Nitric oxide synthase (NOS) is an enzyme expressed in the liver 
that has drawn much attention in the field of IR injury. NOS is activated by liver IR 
and although it appears to modulate IR injury, its exact role is not well understood. 
 
Nitric oxide (NO) is endogenously produced by NOS. Nitric oxide synthase (NOS) is 
an enzyme that catalyses the formation of NO and L-citrulline from L-arginine. The 
transient and volatile nature of NO makes it difficult to measure directly. However, 
because most of the NO is oxidised to NO2- and NO3-, the concentrations of these 
anions (NOx) are often used as a quantitative measure of NO production (Zeballos et 
al. 1995). Koti et al. (2002) found that NOx levels were reduced with liver IR injury 
in a rat partial (70%) hepatic IR model consisting of 45 minutes ischaemia and 2 
hours reperfusion. L-arginine treatment (100 mg/kg intravenously) 10 minutes before 
liver IR significantly increased NOx levels, which resulted in reduced hepatocellular 
injury compared to IR only.  An inhibitor of NOS, L-NAME (30 mg/kg iv) given 10 
minutes before liver IR reduced NOx levels and increased hepatocellular injury 
compared to IR only. These findings are suggestive of NO having a protective role in 
liver IR injury with NO levels falling with prolonged ischaemia followed by 
reperfusion. This is corroborated by other studies on models of partial hepatic 
ischaemia reperfusion (IR) that have shown reduced ischaemia reperfusion injury 
(IRI) in the form of reduced serum transaminases and improved liver microcirculation 
when NO donors are used (Uhlmann et al. 1998, 2000).  In contrast, very high levels 
of NO become injurious, as found by a group using a total heaptic ischaemia model 
consisting of 40 minutes ischaemia and 90 minutes reperfusion. This produces more 
severe liver IRI than the partial (70%) IR model. L-arginine (3 mg/kg iv) as an NO 
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donor given 20 minutes before liver IR resulted in increased liver IR injury and 
conversely L-NAME (5 mg/kg iv) given 20 minutely before IR reduced 
hepatocellular injury (Lin, Wang 2004).  
NOS has two isoforms in the liver: a constitutive endothelial isoform (eNOS) and an 
inducible isoform (iNOS). Their respective contribution to liver IR injury is not well 
understood. Highly specific pharmacological inhibitors or activators of eNOS and 
iNOS are not currently available. Although L-NAME and L-NIL for instance are 
often advertised as inhibitors of eNOS and iNOS ,respectively, the specificity of their 
action on a particular isoform is in fact limited. The use of transgenic models of IR 
offers a robust method of studying the functions of various genes and their products, 
including eNOS and iNOS, thereby providing insights into the molecular mechanisms 
underlying liver IR injury, as discussed in the previous sections. Transgenic double 
knockouts of eNOS (eNOS-/-) and iNOS (iNOS-/-) are available and have been 
studied in models of liver IR injury. 
Transgenic eNOS -/- animals have been used in a partial (70%) hepatic IR model to 
study IR injury. These studies have shown that liver IR injury  is more severe in 
eNOS-/- animals than normal mice. In the eNOS-/- mice there is greater hepatocyte 
apoptosis and necrosis, increased leucocyte infiltration within liver lobules and higher 
serum transaminases compared with normal wild type animals (Kawachi et al. 2000; 
Lee et al. 2001; Hines et al. 2002). Consistent with this, mice with transgenic 
overexpression of eNOS sustain less severe liver IR injury than wild-type mice 
(Duranski et al. 2006). Overall, these findings support a protective role of liver eNOS 
in IR injury. Although there is liver IR injury in normal mice, more severe IR injury 
in mice lacking eNOS suggests that eNOS in normal mice blunts the severity of injury 
resulting from prolonged ischaemia followed by reperfusion. These findings have also 
been corroborated with experiments studying the effects of global combined cold and 
warm liver ischaemia followed by reperfusion in a mouse liver transplantation model 
using either donor wild type or eNOS-/- liver to a recipient wild type mouse. This 
study showed there was greater hepatocellular and histological injury, increased 
hepatocyte apoptosis and increased microcirculatory dysfunction as measured by 
intravital fluorescence microscopy with eNOS-/- donor livers than wild type donors 
(Theruvath et al. 2006). This would indicate that the protective effect of eNOS in liver 
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IRI, at least in a liver transplantation model, requires eNOS expression within the 
liver. 
The current evidence suggests that NO derived from eNOS has a protective effect in 
liver IR injury. The previous studies of liver IR using transgenic eNOS mice have 
used two different endpoints of liver IR injury. In this chapter we describe the 
development of a transgenic eNOS-/- mouse model of partial (70%) hepatic IR for the 
study of the role of eNOS in liver warm IR injury using the three endpoints of liver IR 
injury used in the previous chapter (Chapters 2 and 3). The aim of the experiments in 
this chapter is to study the effect of IR in wild type and eNOS-/- to determine if NOS 
has a central role in liver IR and IPC. 
 
5.2. RESULTS 
 
During the operative procedure all animals remained stable and tolerated anaesthesia, 
IR and IPC. There was no intraoperative mortality in any of the wild type and eNOS-
/- knockout animals. All the endpoints were achieved. The eNOS-/- mice were viable 
at 8 to 12 weeks, appeared as healthy as wild type mice, there were no anatomical 
differences intraabdominally on laparotomy and they were as stable as wild type mice 
under general anaesthesia. 
 
Anaesthesia and Sham Laparotomy in eNOS-/-  versus Wild Type Animals 
 
Although in wild type animals there was no evidence of liver injury in the sham 
group, in eNOS-/- animals there was evidence of liver injury with anaesthesia and 
sham laparotomy. Serum ALT was raised (120+/- 59 IU vs 63+/- 33 IU in wild type 
mice)) and there was histological liver injury, mainly hepatocyte necrosis (Figure 4.1 
and 4.3). There was no statistically significant change in the liver microcirculation in 
the sham group for the duration of the experiment although there was a  trend towards 
reduced microcirculation over the duration of anaesthesia (Figure 4.2). The LDF did 
not differ between eNOS-/-  sham and wild type normal sham groups. 
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Effect of IR on eNOS-/- versus Wild Type Animals 
 
The eNOS-/- animals tolerated the period of liver ischaemia and reperfusion. There 
was acute hepatocellular injury (ALT 3655+/- 1607 vs sham120+/-59IU, p<0.05) and 
histological injury (score  4.75+/-1.3 vs shams 1.7+/-1.3, p<0.05). The IR injury was 
more severe in the eNOS-/-  than wild type animals (P<0.05) (Figure 4.1 and 4.3).  
 
Liver microcirculation was impaired in the eNOS-/- animals undergoing IR 
throughout the 2 hours of reperfusion compared with the sham eNOS-/- group ( 
P<0.01 1-way ANOVA, Figure 4.3).  There was a greater percentage reduction in 
microcirculation with IR in wild type animals at all the time points of measurement 
during reperfusion compared with eNOS-/- mice (wild type 30-40% vs eNOS-/- 10-
20%), but this did not reach statistical significance (P=0.18).  
 
5.3. DISCUSSION 
 
The eNOS-/- knockout model of partial hepatic IR to investigate the role of eNOS in 
IR injury was found to be robust and reliable. In this model sham laparotomy was not 
associated with liver injury in wild type animals, but there was mild liver injury with 
eNOS-/- animals. IR injury was more severe in the   eNOS-/- knockout animals than 
the normal wild type animals. 
 
Unlike wild type animals, in eNOS-/- animals anaesthesia with sham laparotomy was 
associated with a rise in serum ALT and histological injury at the end of 3 hours 
anaesthesia, although there was no effect on liver microcirculation. This indicates that 
anaesthesia alone with sham laparotomy activates physiological and molecular 
mechanisms that would result in liver histological injury, but baseline expression of 
eNOS protects against this. The stress response initiated by laparotomy activates 
inflammatory cascades that result in hepatocellular injury. NO released from baseline 
expression of eNOS in liver dampens this inflammatory response (Okajima et al. 
2004, neutrophil elastase). Without an anaesthesia only without sham laparotomy 
group for eNOS-/- knockouts it cannot be ruled out that isoflurane anaesthetic  
sensitivity contributed to liver injury. Some reports have shown that liver injury can 
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result with isoflurane anaesthetic (Nishiyama et al. 1998) which may be related to 
increase intracellular Ca2+ in hepatocytes (Iaizzo et al. 1990) and reduced liver blood 
flow (Goldfarb, Debaene et al. 1990). In our study, the anaesthetic regimen was not 
associated with microcirculatory dysfunction in the sham laparotomy group of eNOS-
/- animals. This is consistent with previous reports where after sham laparotomy and 
anaesthesia, eNOS-/- livers have the same sinusoidal with and flow velocity (as 
measured by intravital flow microscopy) as wild type livers, indicating no significant 
difference in baseline liver microcirculation with the absence of eNOS (Theruvath et 
al. 2006). Systemically, eNOS-/- mice are hypertensive at baseline, under anaesthesia 
and postoperatively by 20-30% compared to wild type animals with greater MAP 
variability (Huang et al. 1995, 1999; Strauss et al. 1999). These effects are mediated 
through reduced systemic baseline vasodilatation. This may act to increase 
susceptibility to anaesthetic injury by increasing the bioavailability of anaesthetic. 
 
In the eNOS-/-animals there was increased liver IR injury compared to wild type 
animals demonstrated by increased hepatocellular injury and increased histological IR 
severity score. The more severe histological injury resulting from liver IR injury in 
the eNOS-/- animals than wild types was related to increased hepatocyte necrosis 
evident as more extensive pyknotic nuclei, cytoplasmic blanching and loss of distinct 
hepatocellular borders. The demonstration of IR injury in wild type and eNOS-/- 
animals with more severe IR injury in eNOS-/- in this IR model is as noted in 
previous studies using eNOS-/- models of lobar hepatic ischaemia (Kawachi et al. 
2000; Hines et al. 2001).  
The 2 hours reperfusion time following the prolonged 45 minutes ischaemia is too 
early in the phase of IR injury for neutrophils to accumulate within the liver sinusoids 
as seen with longer reperfusion periods in the IR injury process (Kawachi et al.2000).  
This indicates that baseline eNOS partially protects against hepatocellular injury 
occurring with early phase IR injury. It does this by inhibiting hepatocyte necrosis, 
but not by affecting the liver microcirculation in vivo. NO from eNOS acts as a 
scavenger of reactive oxygen species (ROS) and there is evidence that it activates 
survival kinase pathways (Kim JS, Ohshima S et al. 2004)  through guanylate cyclase 
(Duranski et al. 2006).  This would explain a partial protection mediated by baseline 
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hepatocyte eNOS against hepatocellular injury in the absence of a cellular 
inflammatory response. Previous reports have, however, also shown that NO 
maintains perfusion of the hepatic microcirculation (Shibayama et al. 2002) and 
modulates liver injury through its vasodilatory effects (Jaeschke et al. 2006), but this 
has involved the use of exogenous agents, such as inhaled NO, in models of hepatic 
IR rather than in vivo studies of endogenous NO in liver IR.  
In conclusion, we described a mouse model of IR that results in IR injury and that in 
eNOS-/- mice results in more severe liver IR injury than wild type normal mice. This 
shows that eNOS is protective in early phase warm liver IR injury. eNOS exerts its 
protective effects through the reduction of hepatocellular injury, but not by preserving 
liver microcirculation. This would suggest that eNOS within hepatocytes rather than 
sinusoidal endothelial cells blunts the severity of IR injury following liver IR without 
preconditioning. This model should prove useful in investigating the protective 
mechanisms of eNOS in liver IR injury. Having evaluated the effect of anaesthesia 
and IR in the eNOS animal model in this chapter, in the next chapter we wished to 
analyse the mechanism of IPC using the model. 
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Figure 5.1: Serum ALT  in Wild Type and eNOS(-/-) groups. Values are means+/-s.d. 
of 5 animals in each group (*P<0.05 vs. eNOS-/- sham, #P<0.05 vs. WT sham, 
+P<0.05 vs. WT IR). IR=ischaemia reperfusion only; IPC=ischaemic preconditioning 
preceding ischaemia reperfusion. 
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Figure 5.2: Hepatic Microcirculation during reperfusion after Index ischaemia of 45 
minutes in eNOS Knockouts and wild type animals. BL= baseline microcirculation at 
sham laparotomy (time 0); I45= 45 minutes partial (70 %) hepatic ischaemia; R5= 5 
minutes reperfusion after ischaemia; R60= 60 minutes reperfusion after ischaemia; 
R120= 120 minutes reperfusion after ischaemia IR=ischaemia reperfusion only; 
WT=wild type animals; eNOS-/-=eNOS knockout animals. Data points are mean+/-
sem. 
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Figure 5.3: Liver histology eNOS-/- and WT animals. (A) Sections from the experimental groups (400X).  (B) Bar graph summarising 
histological scores. Values are mean +/- s.d. of 5 animals in each group (*P<0.05 vs. sham WT, #P<0.05 vs. eNOS sham, +P<0.05 vs. WT IR). 
WT=wild type animals; IR=ischaemia reperfusion only; IPC= ischaemia preconditioning preceding ischaemia reperfusion.
* *# 
*# + 
Wild Type and eNOS-/- Histological Score 
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CHAPTER 6: 
 
COMPARISON OF EFFECT OF ISCHAEMIC PRECONDITIONING 
(IPC) on eNOS-/- and WILD TYPE ANIMALS 
 
6.1. INTRODUCTION 
 
The role of eNOS in liver IPC is not well understood. A rise in blood and periportal nitric 
oxide (NO) levels is associated with the development of liver tolerance to reperfusion injury, 
which is abolished by adding inhibitors of NO release such as L-NAME. NO donors promote 
liver preconditioning, even in the presence of NO synthase inhibitors (Koti et al. 2002, 
Peralta et al. 1997, Arai M et al. 2001,Peralta et al. 2001). NO appears to act as a trigger in 
early IPC (Rakhit et al. 1999).  Understanding the mechanisms by which NO release is 
activated and how it reduces liver IR injury in IPC offers the possibility of developing 
specific pharmacological agents for clinical use to protect against liver IR injury and its 
sequelae. 
 
Endogenous NO production in liver IR injury is by the two isoforms eNOS and iNOS, but it 
is unclear what the dominant source in vivo is in IPC. Koti et al. (2005) showed in a rat 
model of partial (70%) hepatic ischaemia that early IPC is associated with increased hepatic 
vein nitrate and nitrite (NOx) and with increased eNOS protein expression localised to 
hepatocytes and sinusoidal vascular endothelium associated. Addition of a nonspecific NOS 
inhibitor, L-NAME, abolished the increased expression of eNOS and rise in hepatic vein 
NOx. iNOS expression was absent in all groups. This suggests that eNOS is the source of NO 
in early IPC. This study relied on pharmacological agents to arrive at conclusions about the 
role of eNOS in early IPC. 
 
An eNOS -/- knockout has not been used to study liver IPC and would give robust 
mechanistic insights into the role of eNOS in liver IPC, as the disruption is highly specific 
and complete at the genetic level. In this chapter we studied the effect of IPC on liver IR 
injury in vivo in eNOS-/- and wild type animals (Chapters 2 and 3). 
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6.2. RESULTS 
During the operative procedure all animals remained stable and tolerated anaesthesia, IR and 
IPC. There was no intraoperative mortality in any of the wild type and eNOS-/- animals. All 
the endpoints were achieved. 
 
The effect of IPC followed by IR on eNOS-/- animals 
 
The eNOS-/- animals underwent direct IPC of 5 minutes ischaemia followed by 10 minutes 
reperfusion to the cephalic liver lobes followed by 45 minutes ischaemia of the cephalic lobes 
and then 2 hours reperfusion. Although IPC preceding IR was still associated with liver IR 
injury, the mean serum ALT was reduced by 50% in the IPC+IR group compared to the IR 
group in the eNOS-/- animals, but with 5 animals per group this difference did not reach 
statistical significance (P=0.20). IPC did not reduce the histological liver injury score in 
eNOS-/- groups (P=0.29;   Figure 5.4), unlike wild type animals. IPC failed to reverse the 
reduction in the liver microcirculation found in the in eNOS-/- group (P=0.34, Figure 5.3). 
Taken together there is no protection against IR injury with IPC preceding IR in eNOS-/- 
animals in this model of liver IR. This is in contrast to the effects of IPC in wild type animals 
in this model.  
 
6.3. DISCUSSION 
 
In this chapter we have described a new model for the investigation of the mechanisms of 
ischaemic preconditioning using an eNOS-/- knockout animal. The model was found to be 
robust and reliable. Ischaemic preconditioning (IPC) reduced the hepatocellular injury of IR 
in the eNOS -/- knockouts, although this did not reach statistical significance, but IPC did not 
reduce histological changes or the reduced microcirculation found during the period of 
reperfusion. This would suggest that eNOS is a mediator of the beneficial effect of IPC. 
 
Throughout our study we have used a model of partial (70%) hepatic IR in which liver IR 
injury was demonstrated consistently for wild type and eNOS-/- animals and where IPC of 5 
minutes partial ischaemia and 10 minutes reperfusion reduced IR injury in wild type animals. 
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It was therefore felt reasonable to use the same IPC protocol on eNOS-/- animals to assess the 
role of eNOS in the protective effects of IPC against liver IR injury. 
 
Nitric oxide (NO) has previously been shown to be a key mediator of liver IPC (Peralta et al. 
1999; Koti et al. 2002). IPC is associated with increased nitric oxide metabolites and 
increased expression of nitric oxide synthase in  hepatocytes and vascular endothelium in the 
centrilobular zone (Koti et al. 2002). In the present study it was shown IPC of 5 minutes 
ischaemia followed by 10 minutes reperfusion reduced IR injury in normal wild type animals, 
but the same IPC protocol failed to show significant protection against liver IR injury in 
eNOS-/- animals as demonstrated by no improvement in liver microcirculation, no decrease 
in histological injury and highly elevated serum ALT. This indicates that eNOS is a 
protective mediator of IPC and reduces IR injury by not only reducing hepatocellular injury 
but also by improving liver microcirculation. This would suggest that IPC activates eNOS in 
both hepatocytes and sinusoidal endothelial cells (SECs).  This is consistent with previous 
reports, which have shown that IPC improves liver microcirculation and SEC wall integrity in 
hepatic IR models (Vajdova, Heinrich  et al 2004; Glanemann et al. 2003). In a rat liver 
transplantation model IPC was shown to reduce SEC injury, which is a predominant feature 
of liver donor cold storage and reperfusion injury, by more than 50 %, improving graft 
survival (Arai M et al. 2001). IPC activates eNOS which releases NO. NO activates soluble 
guanylate cyclase (sGC) which catalyses formation of cGMP and GTP which causes 
relaxation of vascular smooth muscle by a number of mechanisms, including inhibiting 
release of the vasoconstrictor endothelin-1 (Rensing et al. 2002; Suematsu et al. 1996; Peralta 
et al. 1996). The cGMP also acts as a second messenger activating downstream survival  
MAP kinase pathways (Carini et al. 2003). 
 
In the present study the model of partial hepatic ischaemia with an index IR of 45 minutes 
ischaemia and 2 hours reperfusion causes greater liver IR injury in eNOS-/- than wild type 
animals. Therefore, a limitation of the present study is that an optimized IPC protocol was not 
used for eNOS-/- animals, as although IPC of 5 minutes ischaemia followed by 10 minutes 
reperfusion before index IR has only very limited protective effect in eNOS-/- knockouts, it is 
possible other IPC protocols may be protective for the more severe injury found in knockout 
animals which involve eNOS independent mechanisms. There is some evidence of this in our 
model, as IPC did reduce serum ALT by 50% compared to the IR only group, but this did not 
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reach statistical significance because of the relatively large standard deviation of the mean 
serum ALT in the knockout animal IR and IPC+IR groups. There is therefore the possibility 
of a type II error for the serum ALT results in the eNOS-/- animals with five animals per 
group, precluding a solid conclusion about whether IPC reduced serum ALT in eNOS-/- 
knockouts. This indicates that this part of the study was underpowered. This could be 
overcome by using at least 7 animals per group based on retrospective power and sample size 
calculation  (α=0.05  and  power  80  %).  
 
Another limitation is that by studying a knockout animal we only obtain information about 
the effect of the presence or absence of a protein, but not about the graded effects of levels 
or timecourse of that protein (in this case eNOS) or the signalling cascades it is involved in.  
 
In conclusion, we described a new mouse model of direct IPC that in wild type mice 
significantly reduces liver IR injury and in eNOS-/- mice has no significant hepatoprotective 
effect against liver IR injury. This shows that eNOS is a protective mediator of direct IPC in 
early phase warm liver IR injury. eNOS exerts its protective effects through the preservation 
of liver microcirculation and by directly reducing hepatocellular injury, most likely by 
activating downstream cell survival signaling pathways. This suggests that IPC activates 
eNOS in both hepatocytes and SECs. This model should prove useful in investigating the 
protective mechanisms of eNOS in direct IPC and liver IR injury.  
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Figure 6.1: Serum ALT  in Wild Type and eNOS(-/-) groups. Bar graph summarising serum 
ALT. Values are mean +/- s.d. of 5 animals in each group (# P<0.05 vs. WT sham, +P<0.05 
vs. WT IR, *P<0.05 vs. eNOS -/- sham. IR=ischaemia reperfusion only; IPC+IR= ischaemia 
preconditioning preceding ischaemia reperfusion; WT=wild type animals; eNOS= endothelial 
nitric oxide synthase; eNOS-/- =eNOS transgenic double knockout. 
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Figure 6.2: Liver microcirculation in WT and eNOS-/- animals. (A) Hepatic Microcirculation 
during reperfusion after Index ischaemia of 45 minutes in Wild Types. (B) Hepatic 
Microcirculation during reperfusion after Index ischaemia of 45 minutes in eNOS Knockouts. 
BL= baseline microcirculation at sham laparotomy (time 0); I45= 45 minutes partial (70 %) 
hepatic ischaemia; R5= 5 minutes reperfusion after ischaemia; R60= 60 minutes reperfusion 
after ischaemia; R120= 120 minutes reperfusion after ischaemia IR=ischaemia reperfusion 
only; IPC+IR= ischaemia preconditioning preceding ischaemia reperfusion; WT=wild type 
mice. Data points are mean+/-sem.  
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Figure 6.3: Liver histology for sham, liver IR only and IPC in WT and eNOS-/- groups. (A) Sections from the eNOS-/- groups (400X).  (B) Sections from WT groups (400X). (C) Bar graph summarising histological scores. Values are mean +/- s.d. of 5 animals in each group (# P<0.05 vs. WT sham, *P<0.05 vs. eNOS -/- sham, +P<0.05 vs. WT IR, &P<0.05 vs. WT IPC). IR=ischaemia reperfusion only; IPC= ischaemia preconditioning preceding ischaemia reperfusion; WT=wild type animals.  
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CHAPTER 7: 
 
COMPARISON OF NOS AND HO-1 Protein EXPRESSION in eNOS-/- 
and WILD TYPE ANIMALS IN EARLY PHASE LIVER IR INJURY 
 
7.1. INTRODUCTION 
 
Endothelial nitric oxide synthase (eNOS) is a key mediator of the protective effects of liver 
ischaemic preconditioning (IPC) in liver IR injury. Studies have shown increased expression 
of hepatocyte eNOS in early IPC and the protection of IPC was abolished with inhibitors of 
NOS (Koti et al. 2005, Serracino-Inglott 2002). 
 
The protective effects of eNOS in early IPC may relate to increased activation and/ or  
expression of eNOS protein. eNOS is activated in a number of ways: by Ca2+-calmodulin , 
phosphorylation by protein kinases (such as PI3-Akt) and association with a number of 
molecules such as hsp-90 (Fleming et al. 1999). It is unclear which of these mechanisms 
dominate in liver IPC. 
 
The role of iNOS in liver IRI and IPC has not been established. Genetic knockouts of 
inducible nitric oxide synthase (iNOS -/-) have been used to study liver IR injury, but the 
various models of liver IR injury have reached some conflicting conclusions. This ranges 
from some studies showing no role for inducible nitric oxide synthase (iNOS) in liver IR 
injury (Kawachi et al. 2000;Khandoga et al. 2002), to iNOS being protective (Lee, Baust 
2001) to others citing iNOS as contributing to the liver injury (Hamada et al. 2009). 
 
Haem oxygenase-1 (HO-1 or heat shock protein 32, hsp 32) has attracted much research 
interest, because of its potential cytoprotective roles in diverse disease and injury states, 
including liver IRI, and its surprising similarities to NOS (Chapter 1.2.14 and 1.3.6). HO-1 is 
an enzyme that catalyses formation of carbon monoxide (CO), biliverdin and Fe2+ from 
degradation of haem. HO-1 is the inducible isoform of haem oxygenase. It is ubiquitously 
expressed in organs, including liver, and circulating nucleated cells. The specific 
mechanism(s) by which HO-1 can mediate cytoprotective functions is not clear, but 
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byproducts generated during the haem catabolism have been suggested as potential protective 
mediators (Fujita et al. 2001; Neto et al. 2004; Nakao et al. 2004; Baranano et al. 2002). 
Inducers of HO-1 (hsp-32) reduce liver IR injury (Shen XD et al. 2005; Kato Y et al. 2003) 
while inhibitors of HO-1 exacerbate liver IR injury (Kato Y et al. 2003). HO-1 has been 
implicated as having a protective role in IR injury through its by-products CO and biliverdin 
which improve liver microcirculation and reduce hepatocellular apoptosis and necrosis 
(Katori et al. 2002). Models of early phase liver IPC have shown increased HO-1 mRNA, 
followed by HO-1 protein expression and increased activity (Patel A et al. 2004; Coito et al. 
2002; Lai IR et al. 2004; Massip-Salcedo M et al. 2006).  
 
HO-1 and NOS have surprising similarities in their regulation. HO-1 and NOS are both up-
regulated by numerous common stimuli, such as reactive oxygen species, cytokines, and 
endotoxin. It is well established that NO donors can activate HO-1 gene expression and 
activity in a variety of tissues (Foresti et al. 1997; Yee EL et al. 1996). Conversely HO-1 
activity can modulate NOS activity (White KA et al. 1992). As there is increasing evidence 
of the protective effects of NOS, particularly the eNOS isoform, and of HO-1 in liver IR 
injury and mounting evidence of crosstalk between NOS and HO-1, it is possible that this 
crosstalk may be occurring in liver IR injury and IPC and form part of the mechanisms of 
protection against IR injury. 
The relationship between HO-1 and eNOS in liver IPC and IR injury in vivo is currently 
unclear. Based on the current knowledge of eNOS, iNOS and HO-1 in liver IPC and IR injury 
and the results from the previous sections, the following experiments were conducted on wild 
type animals measuring eNOS and phosphorylated eNOS to clarify whether eNOS protein 
expression or activation by phosphorylation were affected in our model of partial liver IR and 
IPC (Chapter 2 and 3). Protein expression of iNOS was measured to assess whether this was 
related to liver injury with IPC and IR in wild type animals and eNOS -/- animals. We used  
eNOS-/- knockouts, as well as wild type animals, in the same model to study the in vivo 
levels and timecourse of HO-1 and eNOS. 
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7.2. RESULTS 
 
7.2.1. eNOS  and phosphorylated eNOS (p-eNOS) Western Blot in Wild Type Animals 
 
Expression of eNOS protein was detected in all the experimental groups of wild type normal 
animals. Expression of eNOS was higher in the IR group and the IPC+IR group than the 
control sham laparotomy group reflected by increased band signal intensity normalised to 
βactin  (P<0.05) (Figure 6.1). eNOS expression was higher in the IR only group than the IPC+ 
IR  group, but this difference did not reach statistical significance (P=0.18) (Figure 6.1). 
Phosphorylated eNOS levels were higher in IR and IPC groups than sham (P<0.05), but there 
was no difference between IPC+IR and IR only (P=0.32) (Figure 6.2). Liver harvested from 
eNOS -/- animals were used as a negative control, which showed no expression of eNOS or 
p-eNOS.  
 
7.2.2. iNOS Western Blot in Wild Type and eNOS -/- Animals 
 
Inducible nitric oxide synthase (iNOS) protein was expressed in all the groups of wild type 
mice. There was no difference in iNOS expression in the groups (P=0.22) (Figure 6.3). 
 
Expression of iNOS was detected at low levels in all experimental groups of eNOS -/- 
animals. As with the wild type animal groups, there was no significant difference between the 
levels of expression of iNOS between sham laparotomy (control), IR only and IPC preceding 
IR groups in eNOS-/- animals (P=0.11).  
 
7.2.3. HO-1 Western Blot Results in Wild Type and eNOS-/-Animals 
 
A strong band was detected in the lane containing the positive control (mouse spleen), but no 
bands were detected from any of the liver samples from the experimental groups of wild type  
animals (Figure 6.5). In eNOS -/- animals there were also no HO-1 bands in the experimental 
groups (results not shown). 
 
 
 
 96 
 
7.2.4. HO-1 mRNA RT-PCR Results in Wild Type and eNOS -/- Animals 
 
RT-PCR detected HO-1 mRNA in all groups of normal wild type animals. This was 
confirmed by repeating PCR runs on different liver tissue samples from the same animal and 
different animals for  liver samples obtained at the end of 2 hours reperfusion for the IR 
group and the IPC followed by IR group and at the end of 3 hours anaesthesia for the control 
sham laparotomy group (n=2). There is a suggestion on these runs that HO-1 mRNA levels 
are higher in the IR only and IPC groups than the sham group based on the higher intensity of 
bands on the gels (Figure 6.6). 
 
In eNOS -/- animals liver samples were obtained at the end of 2 hours reperfusion for the IR 
group and the IPC followed by IR group and at the end of 3 hours anaesthesia for the control 
sham laparotomy group, as with normal wild type animal liver samples, for RT-PCR testing. 
RT-PCR detected HO-1 mRNA in all the eNOS-/- knockout experimental groups. Like the 
previous experiments on wild types, there is evidence in eNOS -/- knockouts that HO-1 
mRNA expression is increased by IR with or without IPC compared to sham laparotomy 
(Figure 6.7).  
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7.3. DISCUSSION 
 
In this chapter it was demonstrated in our partial hepatic IR model that both IR and IPC 
increased eNOS protein expression and eNOS activation by phosphorylation. Haem 
oxygenase-1 (HO-1) protein was not expressed, but HO-1 mRNA was expressed in both wild 
type  animals and eNOS-/- animals following liver IR and IPC, indicating that HO-1 
expression is not dependent on expression of eNOS. 
 
It is unclear whether early phase liver IPC protection associated with eNOS is from increased 
eNOS protein synthesis or increased activity of eNOS and how this activation occurs. In our 
model, liver IR resulted in detectable increases in eNOS protein expression and 
phosphorylated eNOS levels (p-eNOS) in the affected lobes compared to sham laparotomy 
groups, although no additional effect of direct ischaemic preconditioning on eNOS 
expression or p-eNOS levels was demonstrated in this time period.   
 
Our results would indicate that the protective effects of eNOS against liver IR injury in our 
model of partial hepatic IR without IPC are mediated by an increase in eNOS activation by 
phosphorylation and eNOS protein expression. It would appear then that the additional 
beneficial effects of IPC in reducing IR injury in our model are not by increased expression 
of eNOS protein or activation of eNOS by phosphorylation, but by activation of eNOS by 
some other mechanism, as there was no additional effect of IPC on expression of eNOS 
protein and p-eNOS levels compared to the IR only group. A possible mode of eNOS 
activation with IPC is by a Ca2+ dependent mechanism. 
 
Our study is the first to investigate and report patterns of phosphorylated eNOS levels in both 
liver IR and IPC. Our findings on levels of eNOS protein expression contrast with previous 
reports using similar partial hepatic IR models of early phase IR injury with index ischaemia 
of 45 minutes and reperfusion of 2 to 3 hours. These reports show either no difference in 
eNOS protein expression with IR or IPC compared to controls (Abu-Amara et al. 2011) or 
reduced eNOS protein with IR and increased eNOS with IPC (Koti et al. 2005). Western 
Blotting is a semiquantitative technique, but without normalisation of band intensities against 
a control protein such as B actin for a given Western blot as used in our study, it is not valid 
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to make any quantitative assertions about levels of protein expression even from a given 
Westen Blot as discussed in the Results section of this chapter.  
 
The role of iNOS in liver IR injury and IPC is more controversial, as some studies indicate 
that it has no role (Kawachi 2000), contributes to increased injury (Lee 2001, Acquaviva 
2008) or even may be protective (Taylor BS 1998, Hsu 2002). In this chapter iNOS protein 
expression was studied in wild type and eNOS-/- animal experimental groups to elucidate 
this. There was detectable iNOS protein expression in all the experimental groups of wild 
type normal animals and eNOS-/- animals, but there was no significant difference between 
the groups.  These findings indicate that iNOS protein expression does not play a role in early 
phase IR injury in our model of partial hepatic IR and IPC.   
 
The conflicting results of the role of iNOS in early phase liver IR injury in different reports in 
the literature may reflect contrasting roles of iNOS and the regulation of its function in liver 
IR injury depending on the duration of liver ischaemia. Partial hepatic IR models with 
prolonged ischaemia of 60 minutes or longer have found that iNOS does have a role in liver 
IR injury (Hamada et al. 2009; Lee, Baust 2001), while models using shorter ischaemia times 
of 45 minutes, as used in our model, have shown no role of iNOS (Kawachi et al. 2000). 
Some of these previous reports have used iNOS-/- knockout animal models of hepatic IR. 
There is evidence, however, that iNOS-/- knockouts show genetic compensation, as discussed 
in the Introduction of Chapter 4 (Hines et al. 2001), so conclusions based on models of liver 
IR using iNOS-/- animals need to be interpreted with caution and bring into question the 
validity of using iNOS-/- animals in liver IR research. 
 
Haem oxygenase-1 (HO-1) has many molecular similarities and interrelationships with NOS. 
There is some evidence that it is protective in liver IR injury and IPC. The relationship of 
HO-1 to NOS in liver IR injury and IPC in vivo is poorly understood.  In our model, HO-1 
protein was not expressed in any of the experimental groups. RT-PCR detected HO-1 mRNA 
in all experimental groups of wild type and eNOS-/- animals over the same timeframe as liver 
samples probed for HO-1 protein, although it was not possible to draw any quantitative 
conclusions about differences in HO-1 mRNA between groups, as RT-PCR is not a 
quantitative technique. 
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Our findings imply that there is increased transcriptional activation of the haem oxygenage-1 
gene (hmox-1 gene) resulting in increased HO-1 mRNA but the timecourse is too short for 
this to be reflected by a detectable increase in HO-1 protein expression. This is consistent 
with previous reports of partial hepatic IR models, where HO-1 protein is typically expressed 
after six or more hours of liver reperfusion (Shen XD et al. 2005; Su H et al 2006) and is 
preceded by an increase in HO-1 mRNA in postischaemic livers reaching peak levels 
typically after around 3 hours reperfusion (Su H et al. 2006). 
 
In our model, HO-1 expression occurs independently of eNOS, as HO-1 mRNA is detected 
both in wild type normal animals and animals having a double knockout at the genetic level 
of enos in all their cells. There have been conflicting conclusions drawn from previous 
studies (Acquaviva et al. 2008; Duranski et al. 2006). It is possible that in these studies the 
use of the pharmacological agents L-arginine and HO-1 inhibitors and activators may have 
influenced other molecular pathways making it impossible to draw firm conclusions of the 
true in vivo interactions of eNOS and HO-1 in liver IR and IPC.  
 
In conclusion, we have demonstrated in a partial hepatic IR model that both IR and IPC 
increased eNOS protein expression and eNOS activation by phosphorylation with no 
additional effect of IPC. This indicates that the protective effect of eNOS with IR alone may 
at least be partly mediated by increased eNOS protein expression and activation by 
phosphorylation. The additional benefits of IPC are mediated by an increase in eNOS 
activation, but not by phosphorylation. Expression of iNOS protein does not play a role in IR 
injury in our model.  Haem oxygenase-1 (HO-1) protein was not expressed in the early phase 
of liver IR injury with or without IPC, but HO-1 mRNA was expressed in both wild type and 
eNOS-/- animals. This indicates that HO-1 expression is not dependent on eNOS activation in 
our model. HO-1 may still have a protective effect in the late phase of IR injury.  
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Figure 7.1: Western Blot of eNOS in Wild Type groups. (A) Bands from Western Blot (B) Summary 
histogram of band density. Densitometric results are expressed as arbitrary units corresponding to 
signal  intensity  normalised  to  βactin.  Values  are  means+/-s.d. of 5 animals in each group. 
IPC+IR=ischaemic preconditioning (5 minutes ischaemia and 10 minutes reperfusion) preceding 
index ischaemia reperfusion (45 minutes ischaemia and 2 hours reperfusion); IR only=index 
ischaemia reperfusion. 
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Figure 7.2: Western Blot phosphorylated-eNOS in Wild Type groups. (A) Bands from Western Blot 
(B) Summary histogram of band density. Densitometric results are expressed as arbitrary units 
corresponding  to  signal  intensity  normalised  to  βactin.  Values  are  means+/-s.d. of 5 animals in each 
group. IPC+IR=ischaemic preconditioning (5 minutes ischaemia and 10 minutes reperfusion) 
preceding index ischaemia reperfusion (45 minutes ischaemia and 2 hours reperfusion); IR 
only=index ischaemia reperfusion. 
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Figure 7.3: Western Blot iNOS in Wild Type groups. (A) Bands from Western Blot (B) Summary 
histogram of band density. Densitometric results are expressed as arbitrary units corresponding to 
signal  intensity  normalised  to  βactin.  Values  are  means+/-s.d. of 5 animals in each group. 
IPC+IR=ischaemic preconditioning (5 minutes ischaemia and 10 minutes reperfusion) preceding 
index ischaemia reperfusion (45 minutes ischaemia and 2 hours reperfusion); IR only=index 
ischaemia reperfusion. 
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Figure 7.4: Western Blot iNOS in eNOS -/-knockout animals. (A) Bands from Western Blot 
(B) Summary histogram of band density. Densitometric results are expressed as arbitrary 
units  corresponding  to  signal  intensity  normalised  to  βactin.  Values  are  means+/-s.d. of 5 
animals in each group. IPC+IR=ischaemic preconditioning (5 minutes ischaemia and 10 
minutes reperfusion) preceding index ischaemia reperfusion (45 minutes ischaemia and 2 
hours reperfusion); IR only=index ischaemia reperfusion. 
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Figure 7.5: Western Blot of HO-1 Wild Type groups. Strong band for HO-1 detected for the spleen 
sample, but no bands were shown in any liver samples from the experimental groups. 
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Figure 7.6: RT-PCR for HO-1 mRNA in Wild Type groups. IR=ischaemia reperfusion only; 
IPC= ischaemic preconditioning preceding ischaemia reperfusion. 
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Figure 7.7: RT-PCR for HO-1 mRNA in eNOS(-/-) groups. IR only=ischaemia reperfusion only; 
IPC= ischaemic preconditioning preceding ischaemia reperfusion. 
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CHAPTER 8: 
 
STUDIES ON THE LATE PHASE OF LIVER IR INJURY AND IPC  
 
8.1. INTRODUCTION 
 
There is evidence that there are two phases of liver ischaemia reperfusion injury (Yokoyama 
et al. 2000): an early phase (starting from 30 minutes after reperfusion to 6 hours afterwards) 
and a late phase (starting 12 hours after reperfusion to 72 hours afterwards). There is some 
evidence that ischaemic preconditioning (IPC) also has two phases (Centurion et al. 2007; 
Caban et al. 2006): an early phase (starting within minutes of reperfusion and lasting up to 6 
hours) and a late phase (starting 24 hours after reperfusion and lasting several days). This has 
been shown in large animal models of warm hepatic ischaemia reperfusion, as well as 
orthotopic liver transplantation (Compagnon et al. 2005). There may be different mechanisms 
for late phase processes, which has relevance to application in clinical practice meaning that 
additional molecular pathways would need to be targeted for comprehensive protection 
against IR injury and its effects (Monbaliu et al. 2009). 
 
In chapter 7 it was shown in the mouse model of early phase partial hepatic IR and IPC that 
HO-1 mRNA expression was increased, but the timeframe of reperfusion was too short for 
HO-1 protein to be detectable, and this did not require eNOS activity, as the same patterns of 
HO-1 expression were observed in wild type normal and eNOS-/- knockout animals. This 
indicates that HO-1 expression occurs independently of eNOS activity under in vivo 
physiological conditions of liver IR injury and IPC. The timeframe of HO-1 expression 
suggests that HO-1 may have a role in late phase IR injury and IPC. 
 
In late phase mouse models of partial hepatic IR, HO-1 protein expression is detectable in 
postischaemic mouse livers after 24 hours reperfusion (Devey et al. 2009). In a mouse model 
of partial hepatic IR using 60 minutes ischaemia with reperfusion from 3 to 48 hours, a 
spatiotemporal relationship of HO-1 expression was established where HO-1 expression was 
induced and HO-1 mRNA levels in livers peaked after 3 hours reperfusion followed by HO-1 
 106 
 
protein expression which was detectable after 6 hours reperfusion peaking at 9 hours 
reperfusion (Su H et al. 2006). 
 
In this chapter, we sought to develop the mouse model of partial hepatic IR and IPC 
established for early phase IR injury to evaluate a model of lobar IR injury and IPC with a 
late phase evaluation of HO-1 expression (Chapter 2 and 3). This model was used to assess 
whether HO-1 protein expression was detected in this model with IR and IPC consistent with 
a delayed timecourse of expression of HO-1 and a possible role in late phase liver IR injury 
and IPC. This model could be used in future studies to develop other mouse models using 
transgenic animals to investigate mechanisms of delayed phase liver IR and IPC. 
 
8.2. RESULTS 
 
Anaesthesia and Sham Laparotomy in Recovery versus Nonrecovery Animals 
 
There was no evidence of liver injury with 3 hours of anaesthesia and sham laparotomy in 
animals terminated at the end of the 3 hours anaesthesia (nonrecovery group)  reflected by 
normal serum ALT and absence of histological liver injury.  (Figure 2 and 3).  There was no 
evidence of hepatocellular injury with 3 hours of anaesthesia and sham laparotomy with 
recovery from anaesthesia and termination after 24 hours (recovery group), reflected by 
normal serum ALT. In the sham recovery group, however, there was evidence of very low 
grade histological injury in the form of occasional sinusoidal congestion (score 1.0+/-0.8). 
 
Effect of IR in Recovery (Late Phase IR) versus Nonrecovery (Early Phase IR) Animals 
 
In the recovery animal IR group, liver IR injury occurred as demonstrated by hepatocellular 
injury (ALT 290+/-97 IU/L vs sham 43 +/-7 IU/L, p<0.05) as well as significant histological 
injury (score  4.2+/-0.8  vs shams 1.0+/-0.8, p<0.05). The hepatocellular injury was more 
severe in the nonrecovery than the recovery animals reflected by significantly higher serum 
ALT in the former (P<0.05) (Figure 2 and 3).   
 
The histological injury scores were not significantly different in the recovery and 
nonrecovery groups (P=0.09).  In the IR only animals with 2 hours reperfusion (i.e. 
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nonrecovery group), liver sinusoidal congestion and hepatocyte ballooning were dominant 
features, but necrosis was less pronounced, while IR with 24 hours reperfusion resulted in 
extensive centrilobular hepatocyte necrosis with little or no sinusoidal congestion or 
hepatocyte ballooning. The Suzuki classification scores histological injury on extent of 
sinusoidal congestion, hepaocyte ballooning and necrosis (Table 1, Chapter 2 Methods).  
 
The effect of IPC in Late Phase IR versus Early Phase IR 
 
All animals underwent direct IPC of 5 minutes ischaemia followed by 10 minutes reperfusion 
to the cephalic liver lobes preceding ischaemia of the cephalic lobes for 45 minutes followed 
by 2 hours nonrecovery animals or 24 hours reperfusion  for nonrecovery  and recovery 
animals, respectively. 
  
IPC reduced the severity of IR injury in the recovery group, demonstrated by a reduction of 
serum ALT (IPC+IR 110+/-37 IU/L  versus IR only 290+/-97 IU/L, P<0.05, Figure 2) and by 
less marked liver necrosis in the IPC+IR group compared to the IR group at the end of 24 
hours of reperfusion (IPC score 2.2+/-0.8 vs IR score 4.2+/-0.8, P<0.05, P<0.05, Figure 3). 
Therefore, direct IPC of 5 minutes ischaemia followed by 10 minutes reperfusion to the 
cephalic liver lobes is protective against both early phase and late phase liver IR injury 
produced by this model of partial hepatic IR. 
 
HO-1 Western Blot in Late Phase IR Model 
 
After 24 hours reperfusion, a strong HO-1 band was detected in the spleen control lane. In 
contrast to the nonrecovery groups which showed no HO-1 bands, faint HO-1 bands were 
detected in the IPC+IR and IR only groups of recovery animals (but not the sham group).  
 
Intraoperative and Postoperative Complications and Animal Survival 
 
During the operative procedure all animals remained stable and tolerated anaesthesia, IR and 
IPC. There was no intraoperative or postoperative mortality in any of the animals. The 
animals in the recovery experiments did not show behaviour indicating distress or pain 
requiring additional analgesia after recovery. All the endpoints were achieved. 
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8.3. DISCUSSION 
 
In this chapter we studied a mouse partial hepatic IR model of late phase liver IR injury and 
IPC. We showed that the hepatocellular injury occured in the late phase of IR injury with 
lower levels of serum ALT in the late phase after 24 hours, but there was greater hepatocte 
necrosis when compared to the early phase of 2 hours reperfusion of this model. Direct liver 
IPC was protective against both early and late phase IR injury in this model. There is a 
delayed expression of HO-1 protein after 24 hours in this model of liver IR. 
 
In our study there was no rise in serum ALT after 3 hours anaesthesia (nonrecovery) or in the 
24 hour sham control group (recovery). This was reflected by no histological injury in the 
nonrecovery sham group, but there was mild sinusoidal congestion in the recovery sham 
group. The stress response initiated by laparotomy activates inflammatory cascades that result 
in hepatocellular injury. Without an anaesthesia only group that does not undergo 
laparotomy, it cannot be ruled out that isoflurane anaesthetic  sensitivity contributed to liver 
injury.  
 
In this mouse model of partial hepatic IR there was IR injury in both the early and late phase 
of IR as demonstrated by increased serum ALT and histological injury scores. The 
hepaotcellular injury is more severe in the early phase as reflected by higher serum ALT after 
2 hours reperfusion than 24 hours reperfusion. This does not necessarily mean the liver injury 
is less in the late phase, as serum ALT is cleared by the animal. ALT may decrease with 
severe injury even on the background of liver failure and histological changes may require a 
significant time period before the degree of injury is demonstrated histologically. 
 
The histological injury of IR injury progresses from mainly sinusoidal congestion and 
hepatocyte ballooning in the early phase after 2 hours reperfusion to mainly centrilobular 
hepatocyte necrosis in the late phase after 24 hours reperfusion. These findings are in 
agreement with those noted from previous reports of early and late phase liver IR injury using 
mouse partial hepatic IR models. These studies have shown that after 24 hours reperfusion 
there is liver IR injury demonstrated by increased serum ALT and histological injury and this 
injury is less than in early phase IR injury (Uchida et al. 2009; Hamada et al. 2009). In these 
models of liver IR injury, partial hepatic IR with 90 minutes ischaemia of cephalic lobes was 
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used and resulted in sinusoidal congestion in early phase IR injury and necrosis and 
progressive neutrophil recruitment in late phase IR injury (Lappas et al. 2006; Hamada et al 
2009; Kato et al. 2002). 
 
In chapter 3, IPC consisting of 5 minutes ischaemia and 10 minutes reperfusion was shown to 
be protective against early phase IR injury in the mouse model of partial hepatic IR. In this 
chapter, the same IPC protocol was used to investigate if it was protective against late phase 
IR injury with the aim of developing a complete model of liver IPC with early and late phase 
IR injury. IPC reduced early and late phase IR injury in our partial hepatic IR model. This 
was reflected by a reduction in serum ALT and histological injury after 2 hours reperfusion 
and 24 hours reperfusion.  
 
This is consistent with previous reports using rat models of hepatic IR, supporting that liver 
IPC reduces hepatocellular and histological injury and its protective actions have two phases 
(Centurion et al. 2007; Cutrin et al. 2002): an early phase (starting within minutes of 
reperfusion and lasting up to 6 hours) and a late phase (starting 24 hours after reperfusion and 
lasting several days). These two phases of IPC have also been found in large animal models 
of warm hepatic ischaemia reperfusion, as well as orthotopic liver transplantation 
(Compagnon et al. 2005).  
 
In chapter 6 it was shown in our model of early phase IR and IPC that HO-1 mRNA 
expression was increased, but no HO-1 protein was detectable. In this chapter, HO-1 protein 
was detected after 24 hours in IPC+IR and IR only groups of animals in our late phase IR 
model. This indicates that in our model of liver early and late phase IR, there is 
transcriptional activation of the HO-1 gene, with HO-1 mRNA detectable after 2 hours 
reperfusion, followed by HO-1 protein expression detectable after 24 hours reperfusion. This 
is as noted in previous reports of models of partial hepatic IR, where HO-1 protein expression 
is detectable in postischaemic livers after 24 hours reperfusion, peaking at 9 hours 
reperfusion, and preceded by HO-1 mRNA expression peaking after 3 hours reperfusion 
(Devey et al. 2009; Su H et al. 2006). 
 
There have been no mouse models studying the role of HO-1 in the protective effects of IPC 
in the late phase liver IR injury. There have, however, been these studies in larger animal 
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models, where liver IPC is associated with increased HO-1 mRNA expression followed by 
HO-1 protein expression, consistent with our results. HO-1 protein expression is not detected 
before 6 hours reperfusion, but HO-1 protein is found in liver 24 hours after reperfusion when 
the levels are higher than with IR alone without IPC (Massip-Salcedo et al. 2006). The 
protection conferred by late phase liver preconditioning is abolished by inhibitors of HO-1 
such as zinc protoporphyrrin (ZnPP) in partial liver ischaemia models (Shen XD et al. 2005), 
ex vivo liver and in vivo orthotopic liver transplantation models (Kato Y et al. 2003).  
 
The mechanistic significance of these patterns of HO-1 expression in late phase liver IR 
injury and IPC is unclear and would need to be explored with further recovery experiments 
assessing effects on endpoints of liver IR injury using pharmacological inhibitors of HO-1, 
transgenic HO-1 animal models (hmox+/-, as double knockouts of HO-1, hmox-/- are not 
viable ex utero) and exploring interactions between HO-1 and eNOS by using eNOS -/- 
animals. A limitation of this model is that two endpoints of IRI were used rather than the 
three endpoints used in earlier chapters, as LDF assessment of liver microcirculation was not 
undertaken. 
 
In conclusion, in this chapter we studied a mouse partial hepatic IR model of late phase liver 
IR injury and IPC, demonstrating that the hepatocellular injury was less severe in the late 
phase of IR injury after 24 hours, but there was greater hepatocte necrosis when compared to 
the early phase of 2 hours reperfusion. Direct liver IPC was protective against both early and 
late phase IR injury in this model. HO-1 mRNA expression precedes HO-1 protein 
expression in our model, consistent with previous reports suggesting that HO-1 may have a 
protective effect in the late phase of IR injury and IPC. This model should prove useful in 
investigating the role of HO-1 in the late phase of direct IPC and liver IR injury. This would 
aid in the development of effective pharmacological agents that target various key signalling 
pathways to reduce liver IR injury in the clinical setting and improve patient outcomes. 
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Figure 8.1: Serum ALT for Nonrecovery and Recovery Experiments.  Groups with 2 hours 
reperfusion are nonrecovery and groups with 24 hours reperfusion are recovery. Values are 
means+/-s.d. of 5 animals in each group (*P<0.05 vs. sham, & P<0.05 vs. IR 2 hr, +P<0.05 
vs. IR 24 hr). IR=ischaemia reperfusion only. IPC+IR=ischaemic preconditioning preceding 
ischaemia reperfusion. 
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Figure 8.2: Histology and Scores for Nonrecovery and Recovery Groups. Groups with 2 hours reperfusion are nonrecovery and groups with 24 
hours reperfusion are recovery. (A) Sections from the nonrecovery and recovery experimental groups (400X).  (B) Bar graph summarising 
histological scores. Values are mean +/- s.d. of 5 animals in each group (*P<0.05 vs. sham, &P<0.05 vs. IR 2hr and IR 24 hr,). IR=ischaemia 
reperfusion only; IPC+IR= ischaemia preconditioning preceding ischaemia reperfusion. 
(B) 
* 
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*& 
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Figure 8.3: Western Blot for HO-1 from 24 hour Recovery Experiments with a spleen 
control (single band).  Two lanes were run on the Western blot for  each of the sham, 
IR and IPC+IR recovery groups and a single lane was run for the spleen control, 
hence one dark band. Weak HO-1 bands were detected in the IR and IPC groups as 
well as a strong band in the spleen control for HO-1. Sham=sham laparotomy; 
IR=ischaemia reperfusion only; IPC=ischaemic preconditioning preceding ischaemia 
reperfusion  
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CHAPTER 9:  
 
DISCUSSION 
 
9.1. A MOUSE MODEL OF LIVER IR INJURY AND IPC  
 
In Chapter 4 we sought to verify liver IR injury occurred in our model and an IPC 
protocol that reduced IR injury. 
 
There was liver IR injury across the three endpoints of serum ALT, histological injury 
and microcirculation (LDF). Various IPC protocols were used, but only IPC 
consisting of 5 minutes ischaemia and 10 minutes reperfusion reperfusion was 
protective against IR injury from  the index ischaemia reperfusion (IR) of 45 minutes 
ischaemia and 2 hours. Systematic studies of different IPC protocols on models of 
partial liver IR showed that IPC of 10 minutes ischaemia (but not 5 or 15 minutes) 
and 10 or 15 minutes reperfusion reduced IR injury, although longer index ischaemia 
times were used of 75 to 90 minutes ischaemia  (Yadav et al. 1999; Teoh et al. 2002).  
 
It would appear that the combination of ischaemia and reperfusion times of IPC that 
are protective vary depending on the severity of the index IR and its context. In our IR 
model, 10 minutes ischaemia is either not protective or requires a longer reperfusion 
time than 10 minutes to initiate IPC protective mechanisms. It appears that 3 minutes 
ischaemia is too short to activate protective mechanisms.  
 
In conclusion, we described and validated a mouse model of liver IR that results in IR 
injury and established a direct IPC protocol that significantly reduces this IR injury.  
 
9.2. COMPARISON OF LIVER IR INJURY AND THE EFFECT IPC in   
eNOS-/- and WILD TYPE ANIMALS 
 
Nitric oxide (NO) is a protective mediator in liver IR injury (Shibayama et al. 2002). 
It is produced endogenously by NOS, but the in vivo role of eNOS in IR injury and 
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IPC is not established. To specifically study the role of eNOS, we used double 
knockout eNOS (eNOS-/-) mice in the same model of liver IR injury from Chapter 4.  
 
Anaesthesia with sham laparotomy in eNOS-/- animals was associated with a small 
rise in serum ALT and liver sinusoidal congestion. The stress response to laparotomy 
activates inflammatory cascades. NO released from liver eNOS dampens this 
response and protects against tissue injury (Okajima et al. 2004). Studies have shown 
that IR injury can also result with isoflurane anaesthesia (Nishiyama et al. 1998), but 
it is unknown if eNOS-/- animals are more sensitive to this.  
 
In our IR model there was increased liver IR injury in the eNOS-/-animals compared 
to wild type animals, demonstrated by increased hepatocellular injury and increased 
histological IR severity score, but the microcirculatory dysfunction between groups 
was similar. This is consistent with previous studies using eNOS-/- models of lobar 
hepatic ischaemia (Kawachi et al. 2000; Hines et al. 2001).  
This indicates that baseline eNOS partially protects against hepatocellular injury in 
early phase IR injury. It does this by inhibiting hepatocyte necrosis, but not by 
affecting the liver microcirculation in vivo. NO from eNOS acts as a scavenger of 
reactive oxygen species (ROS) and there is evidence that it activates survival kinase 
pathways (Kim JS, Ohshima S et al. 2004). This would explain a partial protection 
mediated by baseline hepatocyte eNOS in the absence of an inflammatory response.  
 
NO has been shown to be a key mediator of liver IPC (Peralta et al. 1999; Koti et al. 
2002). IPC is associated with increased expression of eNOS in  hepatocytes and 
vascular endothelium in the centrilobular zone (Koti et al. 2002).  We found that IPC 
failed to show significant protection in eNOS-/- animals with no improvement in liver 
microcirculation, no decrease in histological injury or serum ALT. This indicates that 
eNOS is a protective mediator of IPC by reducing hepatocellular injury and by 
improving liver microcirculation. This would suggest that IPC activates eNOS in 
both hepatocytes and sinusoidal endothelial cells (SECs).  This is consistent with 
previous reports which have shown that IPC improves liver microcirculation and SEC 
wall integrity (Vajdova, Heinrich et al 2004; Glanemann et al. 2003).  
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9.3. COMPARISON OF NOS AND HO-1 PROTEIN EXPRESSION IN eNOS-/- 
and WILD TYPE ANIMALS IN EARLY PHASE LIVER IR INJURY 
 
Previous studies have supported the role of eNOS as the source of NO based on 
localisation of NOS isoforms and Western Blots for isoforms of NOS proteins in liver 
IR injury and IPC models (Hines 2002, Peralata C 2001, Koti 2005, Serracino-Inglott 
2002). It is unclear whether during early phase liver IR that the increased NO from 
eNOS is related to protein expression and eNOS activation. 
 
In our model, we detected increases in eNOS protein expression and phosphorylated 
eNOS levels (p-eNOS) in affected liver lobes, although no additional effect of IPC 
was demonstrated. This would indicate the protective effects of eNOS in liver IR are 
mediated by an increase in eNOS activation by phosphorylation and eNOS protein 
expression. IPC would appear to activate eNOS by another mechanism. eNOS may be 
activated by a Ca2+ dependent mechanism (Dudzinski et al. 2006;2007).  
 
Our findings on levels of eNOS protein expression contrast with previous reports 
using similar partial hepatic IR models of early phase IR injury (Abu-Amara et al. 
2011, Koti et al. 2005). Western Blotting is a semiquantitative technique, but without 
normalisation of band intensities against a control protein such as B actin as used in 
our study, it is not valid to make any quantitative comparisons of protein levels. 
 
Haem oxygenase-1 (HO-1) has molecular similarities and interrelationships with 
NOS. There is some evidence that it is protective in liver IR injury and IPC (Kaizu 
2005; Patel A 2004; Coito 2002; Lai 2004, Massip-Salcedo 2006). We studied the 
expression of HO-1 protein and mRNA. HO-1 protein was not expressed in any of our 
experimental groups. RT-PCR detected HO-1 mRNA in all experimental groups.  
 
This is consistent with previous reports, where HO-1 protein is expressed after six or 
more hours of reperfusion (Shen XD et al. 2005; Su H et al 2006) and is preceded by 
an increase in HO-1 mRNA reaching peak levels typically after around 3 hours 
reperfusion (Su H et al. 2006). In our model, the HO-1 mRNA expression without 
detectable HO-1 protein in eNOS-/- and wild type groups indicate that liver IR is 
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associated with increased HO-1 mRNA expression independent of eNOS. This is 
consistent with microarray studies indicating multiple parallel pathways of protection 
(Knudsen et al. 2012). 
 
The relationship of HO-1 to NOS in IR injury and IPC is poorly understood. One 
study showed administration of the NOS substrate L-arginine increased eNOS and 
HO-1 expression in an in vivo liver IR model and concluded that eNOS causes 
increased HO-1 expression (Acquaviva et al. 2008). In contrast, another study using 
eNOS transgenic overexpressors with various HO-1 inducers and inhibitors found that 
both eNOS and HO-1 activity reduced IR injury independently of each other 
(Duranski et al. 2006). The limitation of using inhibitors/activators of NOS and HO-1 
is that they are relatively nonspecific. Therefore, results may not reflect the 
physiological interactions of eNOS and HO-1 as evaluated in our study.  
 
Haem oxygenase-1 (HO-1) protein was not expressed in our model, but HO-1 mRNA 
was expressed in both normal and eNOS-/- animals following liver IR and IPC, 
indicating that HO-1 expression is not dependent on eNOS. HO-1 may therefore have 
a protective effect in the late phase of IR injury acting in a parallel pathway to eNOS.  
 
9.4. THE LATE PHASE OF LIVER IR, IPC AND HO-1 EXPRESSION 
 
We developed our IR model for early phase IR injury in the previous chapters to 
evaluate a mouse model of late phase lobar IR injury and IPC with reperfusion of 24 
hours with a late phase evaluation of HO-1 expression.  
 
We found that there was IR injury in the late phase (24 hurs reperfusion) of IR. 
Histological changes require a significant time period before the degree of injury is 
demonstrated. The histological injury progressed from sinusoidal congestion and 
hepatocyte ballooning in the early phase to mainly centrilobular hepatocyte necrosis 
in the late phase. These findings are in agreement with previous reports of early and 
late phase liver IR injury (Uchida et al. 2009; Hamada et al. 2009).  
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In our model, direct IPC reduced late phase IR injury. This is consistent with previous 
animal models of late phase IR injury where IPC reduced liver IRI. Its protective 
actions had two phases: an early phase (within minutes of reperfusion and lasting up 
to 6 hours) and a late phase (starting 24 hours after reperfusion and lasting several 
days) (Centurion et al. 2007; Cutrin et al. 2002;Teoh et al. 2003; Matsumoto et al).  
 
In Chapter 7 HO-1 mRNA expression, but not HO-1 protein was detected in early 
phase liver IR and IPC. In our late phase model, HO-1 protein was detected after 24 
hours in all groups of animals. Overall, this suggests that in this model of liver IR, 
there is activation of transcription of the HO-1 gene, with HO-1 mRNA detectable 
after 2 hours reperfusion, followed by activation of HO-1 protein expression 
detectable after 24 hours reperfusion. Previous studies have found that late phase IPC 
protection was abolished by the HO-1 inhibitor zinc protoporphyrrin (ZnPP) in partial 
liver IR (Shen XD et al. 2005), ex vivo liver and OLT models (Kato Y et al. 2003).  
 
9.5. LIMITATIONS OF THE CURRENT STUDY 
 
 A limitation of our model is the small size of the mouse. This limits amounts of 
tissue and blood that can be used for testing. Unfortunately, larger transgenic 
eNOS-/- animals are not readily available as discussed in Chapter 1.2.2.  
 
 Our intraoperative monitoring was limited to core body temperature and 
respiratory rate/depth. Haemodynamic monitoring with blood pressure and 
oxygen saturation provides detailed monitoring on intraoperative animal stability. 
For instance, portal triad clamping causes an initial drop in blood pressure. 
 
 A limitation of using an eNOS-/- knockout to investigate mechanisms of liver IR 
injury is that once a role of eNOS is established, it is unclear whether this effect is 
from  the  absence  of  the  gene’s  mRNA,  protein  or  functional  products.   
 
 There was evidence in our study that there was mild hepatocellular injury in the 
sham group of eNOS-/- animals. It was unclear if this was related to sham 
laparotomy or the isoflurane anaesthetic. This is best addressed by studying 
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eNOS-/- animals that undergo anaesthesia  but  no  surgery  and  a  “sham”  group  
with neither surgery nor anaesthetic. This would separate the effects of sham 
laparotomy and isoflurane anaesthetic in the eNOS-/- animals.  
 
 In our model there was greater liver IR injury in eNOS-/- than wild type animals. 
Therefore, a limitation is that an optimised IPC protocol was not used for eNOS-
/- animals. It is possible other IPC protocols may be protective for the more severe 
injury found in eNOS-/- through eNOS independent mechanisms.  
 
 In eNOS-/- animals, there was a trend towards lower serum ALT in the IPC+IR 
group compared to the IR only group, but this did not reach statistical 
significance.  For  a  power  of  80%  and  α=0.05,  a  sample size estimate of n=10 
reduces the chance of a Type II error. 
 
 There was progressive liver histological injury from 2 hours to 24 hours 
reperfusion. Serum ALT does not reflect this progressive injury, as it is rapidly 
excreted. Serum bilirubin remains elevated with sinusoidal congestion and 
disruption of bile canaliculi. This is routinely used clinically as a marker of 
ongoing liver injury. Future late phase IR models should measure serum bilirubin. 
 
 The LDF probe used was designed for small animal studies and mounted onto a 
portable stand. During ischaemia, mouse liver is very friable and is easily 
damaged by any pressure more than the minimal contact required to obtain 
reliable LDF readings. In future, this could be avoided by using soft tip probes. 
 
 It was not possible to quantitatively comment on whether eNOS was 
predominantly in the phosphorylated form following IR or IPC+IR, as Western 
blotting is only a semiquantitative technique and different antibodies were used 
for the assay for eNOS and p-eNOS.  
 
 RT-PCR is a semiquantitative technique at best. Therefore, trends in different 
levels of HO-1 mRNA expression between groups would need to be assessed by 
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using quantitative real time PCR, rather than semi-quantitative RT-PCR, and 
using larger number of animals per group.  
 
9.6. DIRECTIONS FOR FUTURE STUDIES 
 
We justified the use of a partial liver IR model in Chapter 3. The most common 
clinical scenarios where liver IR injury occurs are in liver resection surgery and OLT. 
Future studies would use a model of liver resection in mice to more closely replicate 
the clinical scenario (Beraza et al. 2007). OLT models in mice are technically highly 
challenging and the animals do not tolerate this procedure well. 
 
Our study findings support that eNOS is the protective mediator of IPC in liver IR 
injury. These findings could be consolidated using a NO donor, such as L-arginine, in 
eNOS-/- animals. If the loss of protection in eNOS-/- animals against IR injury was 
reversed with a NO donor, this would indicate that eNOS derived NO was necessary 
and sufficient for protection against early phase liver IR injury. 
 
Our recovery experiments were exploratory to study late phase liver IR and IPC and 
the timecourse of HO-1 expression. Future recovery studies would assess expression 
of other proteins (e.g. eNOS, phosphorylated eNOS and iNOS). Measurements of 
liver microcirculation in the late phase would provide information on the timecourse 
of microcirculatory dysfunction and its recovery.  The use of a NO donor and eNOS-
/- animals in this late phase IR model will provide a more complete in vivo picture of 
the timecourse and inter-relationships of molecular events in liver IR and IPC. 
 
The mechanistic significance of the patterns of HO-1 expression we observed in our 
model of late phase liver IR injury and IPC is unclear. This would need would further 
exploration with experiments using HO-1 inhibitors/activators, transgenic HO-1 
animals (hmox+/-, as double knockouts of HO-1, hmox-/- are not viable ex utero) and 
exploring interactions between HO-1 and eNOS using eNOS -/- animals.  
 
The benefit of animal models of liver IR and IPC would be translation into clinical 
practice with clinically beneficial reductions in liver IR injury. 
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